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Résumé 
De récents travaux ont mis en évidence que des dysfonctionnements dans l’expression de 
gènes impliqués dans la plasticité synaptique contribuent aux déclins cognitifs qu’on 
observe chez les gens âgés et à la progression de la maladie d’Alzheimer.  Notre étude avait 
comme objectif d’étudier le profil d’expression d’ARNm spécifiques impliqués dans la 
plasticité synaptique chez des rats jeunes et âgés et chez des souris transgéniques 3xTg et 
WT.  
Des expériences en qRT-PCR ont été effectuées dans des extraits de cortex et 
d’hippocampe de rats jeunes et âgés et de souris 3xTg et WT, respectivement.  Les résultats 
ont démontré une augmentation significative de l’expression d’ARNm MAP1B, Stau2, 
BDNF, CREB et AGO2 principalement dans l’hippocampe (régions CA1-CA3) des souris 
3xTg comparé aux souris WT.  Une diminution significative a également été observée pour 
l’ARNm αCaMKII dans le cortex des souris 3xTg comparé aux souris WT.  Contrairement 
à ces observations, aucun changement n’a été observé pour l’expression de gènes impliqués 
dans la plasticité synaptique chez les rats âgés comparé aux rats jeunes.   
Ces résultats démontrent qu’un dysfonctionnement existe réellement au début de la maladie 
d’Alzheimer dans l’expression de gènes spécifiques impliqués dans la plasticité synaptique 
et contribue potentiellement à la progression de la maladie en engendrant un déséquilibre 
entre la LTP et la LTD.  De plus, les différences d’expressions sont particulièrement 
observées dans l’hippocampe (régions CA1-CA3) ce qui est consistant avec les études sur 
la progression de la maladie d’Alzheimer puisqu’il est connu que la région CA1 de 
l’hippocampe est la plus vulnérable à l’apparition de la maladie.  Ces résultats permettent 
une meilleure compréhension des événements moléculaires qui deviennent dérégulés à 
l’apparition de la maladie d’Alzheimer.    
 
Mots-clés : Plasticité synaptique, ARNm, déclins cognitifs, maladie d’Alzheimer, rats 
jeunes, rats âgés, souris 3xTg, souris WT, cortex, hippocampe 
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Abstract 
Recent work has demonstrated that dysregulations in the expression profile of plasticity-
related genes in specific brain regions contribute to age-related cognitive decline and 
Alzheimer’s disease.  The aim of this study was to determine the expression profile of a 
subset of plasticity-related mRNAs in different regions of the brain of young and aged rats 
as well as 3xTg and wild type (WT) mice.   
qRT-PCR experiments were performed in extracts of cortex and hippocampus of young and 
aged rats and of 3xTg and WT mice, respectively.  Results demonstrated significant 
increases in the expression of MAP1B, Stau2, CREB, BDNF, and AGO2 mRNAs, 
especially in the hippocampus (CA1-CA3 fields) of 3xTg mice compared to WT mice.  A 
significant decrease was also observed in the expression of αCaMKII mRNA in the cortex 
of 3xTg mice compared to WT mice.  On the other hand, no significant changes were 
observed in the expression of plasticity-related genes in the hippocampus of aged rats 
compared to young rats.   
These results confirm that alterations in gene expression occur at the onset of AD and 
possibly contribute to the progression of the disease by causing an imbalance between long-
term potentiation and long-term depression. In addition, patterns of significant altered gene 
expression, especially in the hippocampus (CA1-CA3 fields) of 3xTg mice are consistent 
with the progression of AD whereby the hippocampus (CA1 region) is most vulnerable at 
the onset of the disease.  These results provide a better understanding of the molecular 
events that first become disturbed in AD.        
Keywords : Synaptic plasticity, mRNAs, cognitive decline, Alzheimer disease, young rats, 
aged rats, 3xTg mice, WT mice, cortex, hippocampus 
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1 Introduction 
1.1 Memory  
Memory, the process of encoding, consolidating, storing, and retrieving knowledge, 
is achieved through the plasticity of the human brain: the ability of neurons to modify their 
connections to make certain neural circuits more efficient (1).  With aging, as much as 60% 
of the population is affected by learning and memory impairments of varying severity (2).  
These can range from mild cognitive decline to more severe cases such as Alzheimer’s 
disease (AD).  Consequently, the aging population affected suffers from diminished quality 
of life and independence and inadvertently, imposes costly and time consuming demands 
on society and the health care system. 
At the onset of cognitive impairment, specific regions of the brain are especially 
vulnerable and as a result a specific type of memory, termed episodic memory, is impaired 
(3).  This type of hippocampus dependent long-term memory enables the consolidation and 
recollection of information in a determined temporal and spatial context.  Initially, various 
areas of the neocortex process visual, auditory and somatic characteristics of information 
which are then integrated by the hippocampus (4,5).  Repetition via the hippocampal-
neocortical loop allows strengthening of associations among new elements.  Eventually the 
neocortex associates these various properties itself to reconstruct a memory.  
At the molecular level, the ability to strengthen or weaken neuronal associations is 
referred to as synaptic plasticity (1).  The synaptic transmission between neurons can either 
be enhanced by activity via long-term potentiation or depressed by activity via long-term 
depression.   Morphological and cellular modifications ensue due to the actions of several 
plasticity-related mRNAs and proteins and can last from milliseconds to long-lasting 
alterations.  The precise transcriptional and translational regulations as well as the 
localization of these mRNAs and proteins are crucial in maintaining an optimal synaptic 
transmission between neurons.  Throughout the lifespan, apparent age-related changes 
occur in the expression profile of these mRNAs and proteins and can contribute to 
cognitive decline by engendering a dysregulation in synaptic transmission (2,6,7).  
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1.2 Memory and the brain 
Memory is a broad term that encompasses both short-term memory, which can last 
several seconds to several minutes, and long-term memory which may be stored for an 
unlimited duration (8).  Long-term memory is divided into explicit memory (declarative)  
and implicit memory (nondeclarative) – (figure 1) (9,10).  The fundamental difference 
between these types of memories lies in the conscious effort required in remembering 
things and facts (explicit) and the unconscious effort required in remembering procedural 
skills or emotional responses (implicit).  Explicit memory is further subdivided into 
semantic and episodic memories which include the knowledge of facts as well as the spatial 
and temporal context of these facts, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Types of memories. Various forms of memory can be classified as explicit or 
implicit memory.  Adapted from (1). 
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1.3 Brain structures involved in different types of memories 
Various brain structures are involved in the acquisition, consolidation, and 
recollection of the different memory subtypes.  Whereas non-declarative memory relies 
mostly on the neostriatum and cerebellum, declarative memory is processed through the 
medial temporal lobe (11-13).  This region contains the hippocampus and connected areas 
such as the entorhinal, perirhinal and parahippocampal cortex.  The importance of the 
medial temporal lobe in declarative memory consolidation is best described by Nadel and 
O’Keefe’s cognitive map theory which suggests that episodic memory, a subtype of 
declarative memory, is dependent on the hippocampus (14). 
The first and best studied case exemplifying Nadel and O’Keefe’s theory is the case 
of patient H.M.  Due to a severe case of seizures, patient H.M. underwent bilateral surgery 
to remove portions of his temporal lobe including the hippocampus.  After surgery, H.M. 
retained intact reasoning, motor skills, short-term memory as well as long-term memory for 
events that occurred prior to surgery, but he could no longer create new long-term 
memories (15).  A similar phenomenon is observed in patients with damage to the 
hippocampus and in elderly suffering from cognitive impairments (16-18).  In support of 
these observations, the discovery of hippocampal place cells in animals further validates the 
cognitive map theory. The firing of these neurons helps orient animals in their environment 
by providing them with a so-called “cognitive map” (19).   
 
1.3.1 Structural organization of the medial temporal lobe 
At the structural level, the anatomical organization of the medial temporal lobe 
corroborates its importance in the encoding and consolidation of episodic memory.  A 
unidirectional path of various linked structures enables the processing of information in an 
efficient and logical manner.  Essentially, neocortical inputs that process unimodal sensory 
information about object features converge in the perirhinal cortex and lateral entorhinal 
area (20). Alternatively, polymodal spatial information converges in the parahippocampal 
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cortex and medial entorhinal area.  Subsequently, this information reaches the dentate gyrus 
and converges mainly in the hippocampus.  In the hippocampus, the mossy fibre pathway 
projects the information to the CA3 field which relays the information to the CA1 field via 
the Schaffer collateral pathway.  Ultimately, the information enters the subiculum and is 
sent back to the deep layers of the entorhinal cortex where the information was originally 
processed (figure 2) (20,21). 
 
 
Figure 2 Anatomical representation of the hippocampus. Adapted from (22). 
 
Under this system-level consolidation model, the hippocampus is depicted as part of a 
retrieval network for recently acquired memories (5).  As associations amongst the different 
elements of a memory are formed and strengthened via repetition, recent memories become 
gradually transferred to neocortical circuits for long-term storage.  Consequently, the 
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reorganized information can be retrieved independently of the hippocampus upon recall 
(4,5). 
1.4 Synaptic plasticity 
It is important to understand memory acquisition at the level of individual cells.  
Information flows through the different structures of the brain and through the subfields 
within these structures via neurons that communicate by means of chemical synapses.  The 
chemical messages conveyed between neurons result in functional alterations at existing 
excitatory synapses (1).  This creates changes in the efficacy of communication or in other 
words, in the excitability of a neuron, for a short period of time.  For persistent changes to 
occur, anatomical alterations consisting of the loss or growth of new synaptic connections, 
must take place. The process of strengthening particular neural circuits through the 
modification of synapses is referred to as synaptic plasticity.  Donald Hebb best describes 
this process by postulating that “if neuron A connects to neuron B and repeatedly or 
persistently takes part in firing it, some growth process or metabolic change takes place in 
one or both cells such that A’s efficiency, as one of the cells firing B, is increased” (23). 
 
1.4.1 Structure of a neuron 
As aforementioned, the hippocampus is compartmentalized in a way that allows for 
the laminar organization of neurons which provides an optimal layout for a presynaptic 
‘neuron A’ to persistently fire a postsynaptic ‘neuron B’.  An efficient synaptic 
transmission between neurons is possible due to the highly specialized structure and 
function of a neuron.   
A neuron contains four distinct regions consisting of a cell body, dendrites, an axon, 
and axon terminals (figure 3) (24).  Synaptic signals are received as neurotransmitters from 
synaptic boutons on the axon terminals of a presynaptic ‘neuron A’ and form a synaptic 
connection with the cell body and dendrites of a postsynaptic ‘neuron B’. Chemical signals 
are rapidly propagated via the axon of the postsynaptic neuron and if they create a 
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sufficiently large excitation within the neuron, the signal is transmitted to other neurons in a 
similar manner.  
As for the multiple dendrites found on most neurons, they are replete with synaptic 
spines that are specialized in receiving chemical signals owing to particular receptors 
embedded in the cell membrane.  Activation of these receptors causes a series of molecular 
reactions that lead to the transcription and synthesis of mRNAs and proteins, respectively.  
The cell body is the main site for protein synthesis but local translation of mRNAs can also 
take place in dendrites at synapses.  The cell body also contains the nucleus where gene 
activation and transcription take place.  Newly synthesized proteins and transcribed 
mRNAs can be assembled and transported to active synapses in vesicles or multiprotein 
particles in dendrites along tracks known as microtubules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Structure of a neuron.  Adapted from (25) 
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1.4.2 Neuronal network in the hippocampus 
In the hippocampus, the chemical messages are transmitted by pyramidal neurons 
situated in a single continuous layer in the CA1 and CA3 subfields (figure 4) (1,26).  About 
five thousand CA3 pyramidal cell axons converge onto the dendritic spines of a single CA1 
cell (1).  Unlike many parts of the brain where both excitatory and inhibitory synapses are 
present on a single spine of a cell, the CA1 region of the hippocampus is solely comprised 
of cells with one excitatory synapse per spine.  The shape of the spine enables the 
confinement of the molecular reactions that occur during a synaptic transmission thereby, 
allowing each spine to function as a distinct biochemical region.  Therefore, each spine can 
participate in strengthening a specific neural circuit during learning and memory. 
 
 
Figure 4 Pyramidal neurons of CA1-CA3 fields. Adapted from (27). 
 
1.4.3 Long-term potentiation and long-term depression 
The strengthening of a neural circuit for learning and memory is dependent on the 
different forms of synaptic plasticity that exist.  For one, long-term potentiation (LTP) is 
described as the enhancement in synaptic transmission between neurons and is broken 
down into an early (E) and a late (L) component (1).  On the other hand, long-term 
8 
 
 
depression is defined as the diminution of a synaptic transmission by activity.  The regional 
anatomy of the hippocampus is ideal for the physiological recordings of LTP and LTD.  By 
stimulating afferent axons of presynaptic neurons in the CA3 region, researchers can record 
excitatory postsynaptic potentials from the cell bodies of postsynaptic neurons in the CA1 
region.  By doing so, the physiological and temporal activities of E-LTP, L-LTP and LTD 
can be assessed, respectively.  From these recordings, it was established that LTP involves 
an induction phase (E-LTP) that lasts about one hour after stimulation and a maintenance 
phase (L-LTP) that can persist for several days as can LTD (figure 5). 
 
  
Figure 5 E-LTP, L-LTP, and LTD. A) Experimental setup for studying LTP in the CA1 
region of the hippocampus.  The Schaffer collateral pathway is stimulated electrically and 
the response of the pyramidal population of neurons is recorded.  B) Comparison of early 
and late LTP in a pyramidal neuron in the CA1 region of the hippocampus.  The graph is a 
plot of the slope (measure of synaptic efficacy) of the excitatory postsynaptic potential in 
the cell as a function of time.  Apdated from (1).  C) Characteristics of E-LTP, L-LTP, and 
LTD, respectively. 
C
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Multiple molecular mechanisms can explain the electrophysiological phenomena of 
LTP and LTD.  Firstly, E-LTP does not require protein synthesis whereas L-LTP requires 
both mRNA transcription and translation (28-32). In fact, studies have demonstrated that if 
either RNA or protein synthesis is blocked in the CA1 area of the hippocampus, long-term 
memory is disrupted but not short-term memory (33-35).  As for LTD, it solely depends on 
translation.  Despite these differences, LTP and LTD share a common feature in that they 
both require specific glutamate receptors in order to take place.  The main receptors are 
known as the NMDA (N-Methyl-D-aspartic acid) and AMPA (2-amino-3-(5-methyl-3-oxo-
1,2- oxazol-4-yl)propanoic acid) receptors which often co-localize on individual synaptic 
spines (1).  
1.4.3.1 Early long-term potentiation 
E-LTP, is initiated upon a single strong stimulation that causes the release of the 
neurotransmitter glutamate from a presynaptic bouton into the synapse (1).  The release of 
glutamate can be increased by brain derived neurotrophic factor (BDNF) and conversely, 
glutamate increases the transcription and secretion of BDNF (36). Glutamate crosses the 
synapse and binds to receptors on the postsynaptic spine (1).  At first, only the AMPA 
receptors open their channels to allow a flow of ions into the postsynaptic neuron.  NMDA 
receptors remain closed due to their unique characteristic of being both ligand-gated and 
voltage-dependent, a result of ion channel block by extracellular Mg2+ ions.  Once the 
voltage change induced by the flow of ions through AMPA receptors is large enough, Mg2+ 
ions dissociate from their binding sites on the NMDA receptor channels.  Subsequently, co-
activation by two ligands, glutamate and glycine, triggers the opening of NMDA receptors 
resulting in a large calcium influx in the postsynaptic neuron.  
When calcium enters the postsynaptic cell a series of chemical reactions occur that 
eventually lead to the activation of plasticity-related target genes.  The cascade of events 
includes the activation of protein kinases such as calcium/calmodulin protein kinase II 
(CaMKII) and atypical protein kinase C (Pkcz).   The protein kinases work in synergy to 
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phosphorylate AMPA receptors thus, increasing their conductance to ions and their 
responsiveness to glutamate (29,37-40). 
When CaMKII is activated, it is capable of transiently autophosphorylating and its 
activity becomes independent of Ca2+/calmodulin (41).  If this Ca2+/calmodulin 
independent postsynaptic activity is inhibited, LTP induction is blocked, but not LTP 
maintenance (42).  Furthermore, similar to the actions of CaMKII and Pkcz, BDNF 
participates in increasing NMDA single-channel open probability (43,44) and in regulating 
the expression of NMDA receptor subunits in hippocampal neurons (45,46).  This is 
achieved by propagation of an intracellular signalling pathway mediated by the binding of 
BDNF to its receptor Trkβ tyrosine kinase (47).  As a result, the excitability of the synapse 
is temporarily increased during a subsequent synaptic transmission.  The changes that occur 
during E-LTP are short-lived and within one hour, basal conditions are restored.         
1.4.3.2 Late long-term potentiation 
For persistent changes to occur, repeated strong synaptic stimulations (32) must take 
place for E-LTP to translate into L-LTP.  L-LTP can also be induced at a “tagged” synapse 
if “tagging” is accompanied by the capture of “plasticity related proteins” (PRPs) (48).  The 
concept of “synaptic tagging” was suggested by Frey and Morris, based on their 
observation that the induction of L-LTP at a synapse stimulates the synthesis of PRPs.  
PRPs can be captured at a second weakly stimulated synapse, termed tagged synapse, to 
convert a weak short-lived signal into a signal strong enough to generate L-LTP providing 
that the capture occurs within a specific time frame.  Synaptic tagging also ensures that 
only activated synapses become modified via PRPs.   
The best PRP candidate currently known is BDNF (49).  Induction of a weak 
synaptic stimulation accompanied by elevated BDNF expression is sufficient to generate L-
LTP (50,51).  However, this is not the case if BDNF is delivered 70 min after stimulation 
(52) since the lifetime of a tag is about 1 to 2 hours (53).  “Tags” must meet several criteria 
that include being activated by weak stimulation that induces E-LTP only, being activated 
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independent of protein synthesis, and being capable of interacting with PRPs for L-LTP.  
Under this definition, a great potential “tag” is Trkβ; the receptor for BDNF.  
Regardless of the mechanism by which L-LTP is induced, it lasts about 1 to 3 hours 
and requires the translation of dendritically localized mRNAs independent of transcription 
(53,54).  The transcription independent induction phase of L-LTP is followed by the 
transcription dependent maintenance phase which occurs about >4 hours after L-LTP 
induction (55).  The time lag between the induction and maintenance phase results from the 
time required to activate the nuclear transcription of plasticity-related mRNAs, and their 
assembly and transport to the active synapse for local translation.  These events must be 
tightly regulated by various proteins.  
The first regulatory proteins involved in propagating the signal for the onset of the 
maintenance phase of L-LTP include a wide range of protein kinases such as Pkcz, 
CaMKII, and protein kinase A (PKA).  Activation of these kinases initiates a molecular 
pathway that leads to the phosphorylation and thereby, the activation of cAMP responsive 
transcription factor CREB (56,57).  The first kinase identified for CREB activation is PKA.  
Upon synaptic stimulation, PKA becomes activated through dissociation of its subunits 
(57).  The released catalytic subunits can translocate to the nucleus where they can 
phosphorylate CREB (56,57).  CREB is responsible for the activation of genes implicated 
in synaptic structural and functional remodelling as well as in modulation of intrinsic 
excitability (58).  When specific CREB isoforms (CREBα/Δ) are knocked out in mice, 
spatial and contextual memories are impaired (59).  These findings are further supported by 
numerous other studies demonstrating the role of CREB during memory formation (60-63).   
1.4.3.2.1 Transcription 
During synaptic plasticity, transcription is mediated by the concerted action of a 
multitude of transcription factors, such as CREB, that mediate the transcription of specific 
genes upon L-LTP induction.  The immediate early gene Arc (activity-regulated 
cytoskeleton associated protein) has been extensively studied for its role in synaptic 
plasticity.  It is one of the first genes activated at the onset of synaptic transmission and its 
12 
 
 
RNA and protein rapidly localize to dendrites and spines after activition (64,65).  It is 
required for L-LTP and memory consolidation (66,67) as demonstrated in a study in which 
Arc KO mice exhibited enhanced E-LTP while L-LTP was blocked in both the dentate 
gyrus in vivo and in the CA1 region of acute hippocampal slices (68).  Rapid Arc 
expression is necessary for the modulation of postsynaptic density expansion as well as for 
growth of postsynaptic dendritic spines by promoting F-actin stabilization through major 
regulators of F-actin dynamics (69). 
1.4.3.2.2 Assembly and transport 
Newly transcribed mRNAs must be assembled into ribonucleoprotein (RNP) 
transport granules in the nucleus before being transported to distal active synapses.  
Mechanisms must be in place to ensure that the correct mRNAs are assembled and 
transported in specific particles for their precise trafficking to active synapses.  The 
particles in which the proteins and their cognate mRNAs are packaged include other 
proteins; some involved in the translational repression of the mRNAs during transport, 
others implicated in associating with microtubules (70,71), and more as components of the 
translational machinery (72).  
Transport of mRNAs from the cell body to dendrites requires intact microtubules 
(70).  The regulation of microtubule assembly into a functional cytoskeletal network is 
highly dependent on the functions of microtubule associated proteins such as microtubule 
associated protein 1B and 2 ( MAP1B and MAP2) (73).  A disruption in the functions of  
MAP1B and/or MAP2 affects the trafficking of new mRNAs and proteins critical for the 
maintenance of LTP (74) .   
Additionally, various proteins are involved in selecting their respective mRNAs by 
recognizing cis-acting sequences in the 3′-untranslated region (UTR) of the mRNAs (75) 
and enabling the transport of these mRNAs to their final destination (76).  Some of these 
mRNA-binding proteins include hnRNP A2 in cortical and hippocampal rat neurons (77), 
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zipcode-binding protein involved in the transport and translation of β-actin mRNA in rat 
dendrites (78) as well as Staufen proteins.  
The double stranded RNA (dsRNA)-binding proteins Staufen 1(Stau1) and Staufen 
2 (Stau2) are found in distinct RNPs in the cell body and dendrites of mammalian neurons 
(79-82) where they each regulate the microtubule mediated transport of a variety of 
mRNAs (79,83-86). In fact, down-regulation of Stau1 and Stau2 by siRNA reduces the 
amounts of RNA in dendrites of neurons.  For example, down-regulation of Stau1 reduces 
the amount of αCaMKII at synapses (81) while down-regulation of Stau2 reduces the 
amount of β-actin (87) and of a reporter with the  3′-UTR at synapses (88). 
1.4.3.2.3 Translation 
Once at the active synapse, the silenced mRNAs are de-repressed and translated into 
proteins that participate in the growth of new synapses and in the formation of new 
receptors (BDNF and its receptor Trkβ, αCaMKII, Arc, etc – see previous paragraphs).  
CPEB (see section 1.3: post-transcriptional modifications) and possibly Stau1 are some of 
the proteins responsible in regulating the local translation of a subset of mRNAs in an 
activity-dependent manner (89-92). For Stau1, it was demonstrated that it increases the 
translation of a specific subset of mRNAs by binding to their 5’ end (89). 
It can be inferred from the above information that LTP is a complex phenomenon. It 
includes a variety of steps in which specific regulatory proteins participate in ensuring that 
an effective synaptic transmission can take place between neurons.  However, it is the 
determination of the interaction between LTP and LTD in a neuron that will ensure that a 
distinctive neural circuit will be reinforced for enhanced memory and learning.   
 
1.4.3.3 Long-term depression 
Similarly to LTP, LTD is a complex molecular event but unlike LTP, transcription 
is not required since pre-localized mRNAs are translationally activated upon LTD 
induction (93).  LTD is initiated upon multiple low frequency stimulations that cause small 
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rises in calcium via NMDA receptors (94).  The low calcium concentration is responsible 
for the distinctive cascade of events that prompts the activation of protein phosphatases 
during LTD compared to protein kinases activated during LTP (95).  A few advances have 
been made regarding the precise phosphatases that are activated during LTD.  It has been 
demonstrated that postsynaptic addition of phosphatase inhibitors that primarily target 
calcineurin or protein phosphatase 1 (PP1) prevent LTD (96).  Protein phosphatases are 
involved in the de-phosphorylation of AMPA receptors thus reducing their open channel 
probability (97).  In addition, the change in phosphorylation is accompanied by the 
internalization of these receptors (98-100). 
Besides its role in LTP, Arc was found to be crucial for LTD (101,102) by 
facilitating endocytosis of AMPA receptors through its interaction with endocytic proteins 
(66,103).  This event is inhibited upon LTD induction by acute blockade of new Arc 
synthesis (101).  In reference to LTD, Arc mRNA translation is believed to be regulated by 
the fragile X mental retardation protein (FMRP) (104) known to be a key player in LTD 
(105).  Indeed, activation of Arc is absent in Fmr1 KO mice (102).  FMRP associates with 
a subset of mRNAs, including Arc, and possibly acts as a negative regulator of translation.  
This theory is based on the observation that in the absence of FMRP, there is excess protein 
synthesis that leads to the increased internalization of AMPA receptors and exaggerated 
LTD (106).  
Furthermore, other candidates, including MAP1B that co-localizes with FMRP in 
dendrites of cultured neurons (107), are thought to play equally important roles in the 
internalization of AMPA receptors during LTD (104,108).  It was shown that the rapid 
synthesis of MAP1B is linked to the internal trafficking of AMPA receptors (109) and that 
the basal expression of MAP1B is augmented in hippocampal slices of Fmr1 KO (110).  
Conversely, the expression of MAP1B in dendrites is reduced in the absence of Stau2.  
Specifically, Stau2 knockdown, but not Stau1 knockdown, with siRNA in primary 
hippocampal neurons blocks LTD and decreases the endogenous expression of MAP1B 
protein as well as the level of a reporter with the MAP1B 3’UTR that is transported to 
dendrites (88).  It also prevents the dissociation of this reporter from Stau2 mRNA transport 
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granules.  Consequently, translational activation of MAP1B is inhibited thus, preventing 
MAP1B dependent AMPAR internalization required for efficient LTD.  Therefore, Stau2 is 
thought to be required for the loading of MAP1B mRNA into transport granules, for its 
transport within these granules to active synapses, and for its local translational activation 
by way of dissociation with MAP1B mRNA.  
All of the events described for LTD and LTP rely on the precise and accurate 
function of plasticity related proteins.  Any disruptions in the expression and activity of a 
protein can hinder the efficacy of a synaptic transmission.  For that reason, strict 
transcriptional and translational regulations of plasticity-related mRNAs and proteins exist.     
1.4.4 Transcriptional and translational regulations of plasticity related 
mRNAs and proteins 
 Transcriptional and translational regulations are crucial in preventing ectopic and/or 
altered expression of synaptic plasticity-related mRNAs and proteins which could 
otherwise result in various defects such as fragile X syndrome (caused by the absence of 
Fmr1 gene expression) (111), Alzheimer’s disease (caused by accumulation of Aβ peptides 
due to disruption of APP metabolism) (112), and more. Translational repression via RNA-
binding proteins and microRNAs (miRNA) as well as polyadenylation of mRNAs has 
emerged as important post-transcriptional regulations (113,114). Similarly, post-
translational modifications such as phosphorylation, adenylation, and methylation are 
crucial in altering the activity of a protein (115-117).  
1.4.4.1 Post-transcriptional modifications 
 Transcription is the first regulatory step in gene expression.  Following 
transcription, mRNAs are assembled in ribonucleoprotein transport granules for their 
export from the nucleus to the cytosol.  During transport, mRNA translation is silenced by 
repressors associating to specific recognition sequences in the 3’UTR of a mRNA (118-
122) or by the presence of an inhibitory RNA structure in the 5′-UTR to block translation 
initiation (123,124). 
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 A great example is the cytoplasmic polyadenylation element protein (CPEB) that 
regulates the polyadenylation (poly(A)) of the 3’ end of a subset of mRNAs.  These 
mRNAs contain CPE recognition sequences in their 3’UTR that bind to CPEB (125).  
Translation can only be initiated when CPEB becomes phosphorylated by a protein kinase 
Aurora (116).  This induces CPEB to interact with proteins involved in the recruitment of a 
poly(A) polymerase for the process of polyadenylation (117).  This step is thought to 
increase translation (126).  A likely target of polyadenylation during synaptic plasticity is 
the 3’UTR CPE-containing N-actin mRNA in Aplysia (127).  Polyadenylation of this 
mRNA was shown to occur in response to stimulation with serotonin (128,129).  
Furthermore, it was demonstrated in mice that αCaMKII contains two CPEs in its 3′UTR 
(130) thereby, making it another potential candidate to be regulated by CPEB via the 
addition of a poly(A) tail.  
 miRNAs also take part in the tight spatial regulation of mRNA translation in 
neuronal dendrites (131).  miRNAs represent an extensive class of small non-coding RNAs 
that act as post-transcriptional regulators of gene expression.  They have been discovered in 
a plethora of tissues, including the nervous system and fittingly, have a widespread role at 
various stages of synaptic development and during synapse function and plasticity.  In post-
mitotic neurons, many miRNAs are associated with translation regulatory complexes (132) 
where one miRNA can control the fate of a few hundred different synapse-relevant mRNAs 
simultaneously (133).   
 miRNAs result from a multi-step maturation process starting with the transcription 
of miRNAs into primary miRNAs (pri-miRNAs) (134,135).  Cleavage of pri-miRNAs 
produces precursor hairpin miRNAs which are exported to the cytoplasm to be further 
processed by the RNase Dicer. The end product is a mature single-stranded miRNA loaded 
into a multi-protein miRNA-induced silencing complex (miRISC). An important 
component of this complex with regard to synaptic function is the Argonaute protein.  The 
miRNA within the complex is guided to target mRNAs in order to extensively bind, albeit 
imperfectly, to sequences usually present within the 3’UTR of these mRNAs.  This results 
in the translational repression and/or degradation of the mRNAs in question. 
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 In particular, miR-134 is known for its role in suppressing the translation of LIMK1 
mRNA in dendrites of mature hippocampal neurons.  LIMK1 is a kinase that promotes 
actin polymerization and spine growth (136).  The miR-134-LIMK1 association seems to 
be regulated by synaptic activity whereby increased levels of BDNF release LIMK1 from 
the inhibitory effects of miR-134.  miR-138 is another miRNA with a role in spine 
morphogenesis.  miR-138 acts on the depalmitoylation catalytic enzyme APT1 which 
participates in modulating the actin cytoskeleton of dendritic spines (137).     
1.4.4.2 Post-translational modifications 
Phosphorylation is a major post-translational modification that, in most cases, 
induces the activation of a protein.  The constitutively expressed CREB protein is well 
known for being subjected to activation through phosphorylation (115). In the context of 
synaptic transmission, a signalling pathway originating from activation of NMDA 
receptors, leads to an increase in cAMP.  In turn, cAMP activates PKA and the mitogen-
activated protein kinase (MAPK) and both proteins translocate to the nucleus where they 
phosphorylate an activator form of CREB (138,139).  This activator form is responsible for 
the stimulation of gene expression for target genes containing a cAMP responsive element 
(CRE) (140).   
 The regulatory mechanisms described must remain functional for the maintenance 
of a healthy cognitive status.   Cognitive decline associated with aging and 
neurodegenerative diseases arises when disturbances occur in the expression and/or 
function of plasticity-related mRNAs and proteins that bring about changes in the efficacy 
of synaptic transmission.    
 
1.5 Aging and cognitive decline 
 Aging is associated with learning and memory impairments, especially 
hippocampus-dependent spatial memories.  Unfortunately, due to the limited knowledge 
about the etiology of cognitive impairment associated with aging, few pharmaceutical 
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interventions have proven to be effective in preventing and/or treating age-related memory 
loss.  Currently, it is established that during normal aging, various other structural 
modifications are attributed to cognitive decline despite the lack of significant 
neurodegeneration.  Neurons in the cerebral cortex and especially in the medial temporal 
structures undergo attrition of dendritic branches, loss of dendritic spines and loss of 
synapses (141-143).  These changes contribute to the decreased efficiency in relaying 
information through the perforant, mossy fibre, and Shaffer collateral pathways in aged 
rodents not to mention that they are likely a result of dysregulations in the transcription and 
translation of plasticity-related mRNAs and proteins. Such disruptions lead to defects in 
cytoskeletal integrity, microtubule-dependent transport, synaptic functions, and 
neurotransmission (6,7,144-146). 
 The effects of these modifications can be observed in experimental settings.  
Importantly, with regards to hippocampus-dependent spatial memory, there is ample 
evidence that aged rats that undergo the Morris water maze test show deficits in recalling 
the path to the hidden platform after several trials (when the elapsed time between trials is 
long) when compared to young rats (147-155).  Additional electrophysiological studies 
substantiate these findings by providing LTP and LTD recordings in rodent models of 
healthy aging that suggest perturbations in hippocampal plasticity during aging.  These 
recordings display decreased basal synaptic transmission (156), enhanced LTP threshold 
(157), decreased LTP maintenance (158), altered LTP mechanisms (159), and increased 
chances of LTP reversal (160) in aged rodents compared to young ones.  There also appears 
to be facilitated LTD and hence, not surprisingly, an imbalance in synaptic transmission 
whereby LTD prevails over LTP (157,161,162). 
 Each one of the altered electrophysiological recordings observed in aged rodents is 
associated to defects that occur at the molecular level.  For example, significant decreases 
in proteins such as SNAP25, syntaxin 1, VAMP2, and synaptophysin (2,163) critical in the 
docking and fusion of presynaptic vesicles, and in the scaffold protein PSD95 (7,164,165), 
have been observed in aged rodents.  These proteins are essential for the formation of a 
functional synaptic contact.   Causally, a decrease in their expression can help explain the 
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diminution in basal synaptic transmission and in LTP maintenance in aged rodents.  More 
specifically, it may provoke slowed endocytic replenishment and/or abolished exocytosis of 
synaptic vesicle pools as well as impaired receptor aggregation (PSD95) upon prolonged or 
intense stimulation of synaptic transmission (166,167).    
 Furthermore, perturbations in LTP maintenance can arise from defects in the 
expression or function of individual mRNAs and/or proteins.  Immediate early genes (IEG) 
such as Arc represent an important class of transcription factors that are transiently and 
rapidly activated to regulate the expression of target genes involved in synaptic plasticity 
(168,169).  One such IEG is zif268.  Normally, Zif268 expression increases during 
hippocampus-dependent spatial orientation tasks (170) but in aged rodents that express 
spatial memory impairments, resting levels of zif268 mRNAs are decreased in the CA1 and 
CA2 areas of the hippocampus and in the neocortex (171).  These results demonstrate that 
zif268 expression may play an important role in the maintenance of intact spatial memory 
of aged rodents. 
 A dysfunction in the activity of an individual protein can also impair synaptic 
transmission.  The previously discussed CREB protein (sections 1.2 and 1.3) shows 
phosphorylation dependent activity upon LTP induction.  There is evidence for the absence 
of change in the resting expression of CREB in the hippocampal CA1 region and dentate 
gyrus of aged rodents with cognitive decline when compared to young rodents (172,173).  
In contrast, there is a reduced amount of phosphorylated CREB activity that is noticeable in 
the same aged rodents.  Over-expression of CREB in aged rodents can partly rescue age-
related memory changes (174).  This demonstrates the great importance in the activation 
status of CREB for its effective role in synaptic plasticity.  The decreased activity of CREB 
may be partially responsible for the increased LTP reversal observed in aged rats due to 
decreased activation of target genes important in maintaining LTP.  
 Another salient study offered enlightenment for the facilitated LTD observed in 
aged rodents suffering from cognitive impairments.  VanGuilder H.D., et al. demonstrated, 
in hippocampal slices of aged rats, an increased expression of hippocalcin, a protein 
involved in facilitating LTD through calcium sensitive dynamics (2).  Moreover, alterations 
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in the subunit composition of AMPA and NMDA receptors may exacerbate LTD 
prevalence.   The subunit subtypes of NMDA and AMPA receptors have differing kinetics 
that dictate whether LTP or LTD will take place (175-178).  For example, the GluR2 
AMPA receptor subunit prevents calcium permeability through the receptor channel.  Aged 
cognitively-impaired rodents show a decrease in the GluR2 subunit which renders AMPA 
receptors more permeable to calcium.  Increased calcium permeability augments 
susceptibility to excitotoxicity and postsynaptic calcium concentrations determine the 
strength and direction of synaptic transmission (179-182).  Therefore, altered calcium 
homeostasis can result in a wider range of low-frequency activity patterns thereby, 
triggering excessive LTD (183-185).  
 As for NMDA receptors, they are made up of an obligatory NR1 subunit and two 
additional NR2 subunits: NR2A and NR2B (186).  The NR2A or NR2B subunit governs at 
different developmental stages (187,188).  One study determined that the expression 
profiles for both types of NR2 subunits shift in a similar manner in both aged rodents 
suffering from cognitive impairment and young rodents (7).  However, they found an 
increase in NR1 subunits in aged rodents.  These researchers speculated that the additional 
NR1 subunits may represent non-functional subunits that could bring about the 
internalization of NMDA receptors.  Conversely, another study observed an increased 
NR2A/NR2B ratio in the hippocampus of aged memory-impaired mice as compared to 
young adults (189).  This led to changes in the induction thresholds for LTP.  Despite the 
differences between studies, the outcome remains the same. Altogether, these findings 
provide insights into possible mechanisms underlying the predominance of LTD over LTP 
as well as the enhanced LTP threshold observed in aged cognitively- impaired rodents.  
 NMDA receptors in the hippocampus are also susceptible to altered calcium 
homeostasis; (162,190-192) a process that is regulated by two different calcium sources 
during synaptic activity.  Voltage-dependent calcium channels (VDCCs) as well as 
intracellular calcium stores release calcium during synaptic transmissions and their activity 
is altered in aged hippocampal neurons (193,194).  For instance, aged rodents display 
greater numbers of VDCCs in the CA1 region of their hippocampus (195) and thus, cause 
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an imbalance towards an increased dependence on a form of LTP that relies on VDCCs 
rather than NMDA receptors (196-198).  Consistent with this, the activity of NMDA 
receptors is reduced in the hippocampus of aged rats (199).  Such disturbances have 
important implications for LTP induction which henceforth, requires a greater stimulus to 
be triggered via the NMDA receptors.  This represents an altered mechanism by which LTP 
can take place and by which its threshold can be increased.   
 All of the aforementioned alterations observed in cognitively-impaired aged rodents 
occur in the absence of significant neural loss.  It is difficult to imagine the increased 
detrimental effects that neurodegeneration can have on the structural, cellular, and 
molecular processes that take place during synaptic transmission.  These processes will be 
reviewed for a more severe form of cognitive decline exhibiting neurodegeneration that is, 
Alzheimer’s disease (AD).  
 
1.6 Alzheimer’s disease 
 Alzheimer’s disease is a fatal neurodegenerative disease afflicting over 35 million 
people worldwide and representing 70% of dementia cases in the world.  Its prevalence is 
constantly rising as a consequence of the general increase in the aging population which is 
expected to quadruple by 2050 in the United States (200). Despite the ongoing studies and 
our better understanding of the disease, there are currently no effective treatments available 
to cure Alzheimer’s disease.  Its emergence is most often sporadic and in a population aged 
over 65 years. However, about 5% of cases present with a less common form known as 
familial Alzheimer disease (FAD) which usually strikes sooner (201).  FAD is the result of 
mutations in specific genes including the amyloid precursor protein (APP), presenilin 1, 
and presenilin 2 genes.  Regardless of its cause of onset, Alzheimer disease has detrimental 
effects on the quality of life of those affected and imparts costly burdens to the public 
health sector.   
 At the neuropathological level, Alzheimer’s disease is characterized by cerebral 
atrophy which is especially apparent in the hippocampus but also affects the neocortex 
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(202).  In addition there are manifestations of neuronal cell death, neuroinflammation, 
synapse loss, and the accumulation of two specific types of lesions.  These lesions first 
appear in the medial temporal lobe (203,204) and consist of extracellular senile plaques 
made up of aggregated amyloid-beta (Aβ) peptides (205) and intracellular neurofibrillary 
tangles (NFT) (206) composed of hyper-phosphorylated forms of the tau protein (figure 6) 
(207).  
 
 
Figure 6 Lesions in Alzheimer’s disease. A) Schematic representation of senile plaques 
and neurofibrillary tangles.  Adapted from (208).  (B) Histological representation of senile 
plaques (Amyloid) and neurofibrillary tangles (NFT). Adapted from (209). 
  
NFT arise from a dysregulation in the phosphorylation state of tau (210).  Tau is a 
microtubule-associated protein that participates in the stabilization and regulation of 
microtubule dynamics necessary for neurite outgrowth, morphogenesis and axonal 
microtubule-dependent transport. In its de-phosphorylated state, tau’s affinity for 
microtubules is reduced thereby, promoting their depolymerisation.  In contrast, in its 
phosphorylated state, tau binds to microtubules and enhances their stability (211,212).  
Hyperphosphorylation of tau in Alzheimer’s disease hinders the microtubule network and 
promotes self-assembly of tau into paired helical filaments (212,213).  
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On the other hand, Aβ peptides present in senile plaques are cleavage products of 
APP (214).  A dysfunction in the metabolism of APP processing results in excessive Aβ 
fibril accumulation of 39-42 amino acids long.  The 40 (Aβ40) and 42 amino acid residues 
(Aβ42) are the most prevalent while the Aβ42 fibril has a higher propensity to form 
aggregates.  The translational regulation of APP is carried out by FMRP which when bound 
to APP mRNA, represses its translation (215). FMRP may therefore play an important role 
in the pathogenesis of Alzheimer’s disease if its expression is disrupted as seen in fragile X 
mental disorder. 
Similar to the electrophysiological recordings described for cognitive decline (see 
section 1.4) the recordings observed for Alzheimer’s disease display inhibited LTP (216) 
and facilitated LTD in the presence of oligomeric Aβ in hippocampal synapses (217).  The 
mechanisms underlying the disruptions in LTP and LTD include partial inhibition of 
NMDA receptor activity due to Aβ deposition (218) which provokes decreased calcium 
influx through the NMDA channels. The resultant disruption of calcium homeostasis 
causes the activation of calcineurin; a key player involved in the internalization of NMDA 
and AMPA receptors (219,220).  Internalization of NMDA receptors also occurs via 
dephosphorylation of NR2B subunits by oligomeric Aβ induced-phosphatases (221).   
Furthermore, reduced calcium concentration limits downstream events such as 
activation of plasticity related proteins including CaMKII, MAPK, and Akt/protein kinase 
B (222).  All of these events lead to Aβ mediated dendritic spine loss and altered LTP and 
LTD mechanisms.  
Other plasticity-related proteins downstream of receptor activation are dysregulated 
in Alzheimer’s disease.  The previously discussed CREB protein (section 1.2: late long-
term potentiation) is downregulated in the brains of Alzheimer mice (223).  As a result, its 
mRNA and protein levels are lowered thereby, decreasing the phosphorylation-dependent 
activation of the protein.  The underlying cause appears to be the oxidative stress caused by 
the accumulation of Aβ fibrils.  In the presence of antioxidants, the adverse effects of 
oxidative stress on CREB are prevented and so CREB can resume its normal function as an 
activator of target genes.  Under stress conditions, the target genes under the control of 
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CREB are also affected.  CREB target proteins such as BDNF, and anti-apoptotic proteins 
Bcl-2, BIRC3, and BIRC4 are downregulated while the pro-apoptotic protein Bax is 
increased in Alzheimer mice.  Therefore, decreased CREB activity ultimately leads to 
neuronal apoptosis, a major hallmark of Alzheimer’s disease. 
In addition, miRNAs may also play an important role in the translational regulation 
of APP in Alzheimer’s disease.  Various miRNAs have been recognized to bind the 3’UTR 
of APP mRNA (224-226).  In human brains with Alzheimer, the level of miR-106b is 
significantly reduced (225).  However, there is no convincing evidence of a correlation 
between miRNA levels and APP in Alzheimer tissues.  However, regulation of APP by 
miRNAs has not been ruled out.  In rat hippocampal neurons, silencing of AGO2, a RISC 
protein involved in the miRNA pathway (see section 1.3) was shown to increase APP 
protein levels (226).  Further investigations demonstrated the effects of the brain-enriched 
miR-10 on APP levels.  Inhibition of endogenous miR-101 increased APP levels whereas 
overexpression of miR-101 significantly reduced APP levels and consequently Aβ 
aggregates decreased as well.  In agreement with these observations, miR-101 is 
downregulated in the cerebral cortex of patients afflicted with Alzheimer’s disease 
(227,228).  
As can be deduced from the above information, Alzheimer’s disease exhibits similar 
dysfunctions in mRNA and protein expression, in protein activity and in transcriptional and 
translational regulations as observed in age-related cognitive decline.  The main differences 
are the presence of senile plaques and neurodegeneration in Alzheimer’s disease compared 
to memory impairments in elderly.  Despite these differences, the key players involved in 
synaptic plasticity are equally affected in both cases.       
1.7 Hypothesis, aims, and rationale 
1.7.1 Hypothesis 
The expression of plasticity-related mRNAs will be altered in aged rodents and in 
transgenic rodent models showing early stages of AD.  More specifically, the expression of 
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mRNAs mainly involved in LTD will increase whereas the expression of mRNAs mainly 
involved in LTP will decrease and in this manner, cause an imbalance between LTP and 
LTD whereby LTD will prevail over LTP.  The disturbances in mRNA expression will be 
most prevalent in the hippocampus (CA1-CA3 fields) than in other regions of the brain 
such as the dentate gyrus or the cortex.  In addition, the genes affected will differ from one 
brain region to the other.   
1.7.2 Aims 
1) To study the expression of plasticity-related mRNAs in the hippocampus (CA1-
CA3 fields), dentate gyrus, and cortex of 3xTg mice showing early stages of AD 
and their wild-type counterparts by means of RT-qPCR experiments.   
2) To study the expression of plasticity-related mRNAs in the hippocampus and cortex 
of young (3 months old) and aged (24 months old) Fisher 344 rats by means of RT-
qPCR experiments. 
1.7.3 Rationale 
The morphological modifications of neurons that occur in the cerebral cortex and 
more notably in the medial temporal structures where the hippocampus is located (141-
143), are the outcome of disturbances in the transcription and translation of plasticity-
related mRNAs and proteins which together, results in a less efficient synaptic plasticity 
within these structures (6,7,144,145,229).  During aging (157,161,162) and AD (216,217), 
these defects cause an imbalance between LTP and LTD whereby LTD starts prevailing 
over LTP.  Therefore, the expression of mRNAs mainly involved in LTD should increase to 
help explain the increase observed in LTD whereas the expression of mRNAs mainly 
involved in LTP should decrease to help explain the inhibition of LTP observed in these 
pathologies. 
Additionally, during age-related cognitive decline and AD, progressive cognitive 
decline and neurodegeneration (in the case of AD) occur in a sequential process across 
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brain tissues, with the temporal lobe being affected earlier than the frontal part of the cortex 
(3,203).  Thus, changes in the expression of plasticity-related genes most likely appear at a 
later stage in the cortex than in the hippocampus.  Furthermore, Kaiwen He et al. (230) 
demonstrated that the mechanisms for synaptic plasticity might diverge depending on the 
brain region.  Therefore, the genes that become dysregulated in age-related cognitive 
decline and AD might differ across brain tissues and for different sub-regions within these 
tissues. 
For example, the hippocampus contains distinctive anatomical regions consisting of 
the CA1 field, CA3 field, and the dentate gyrus all of which possess unique molecular and 
biophysical properties (231).  Whereas the CA1-CA3 sub-regions are made up of four 
layers of pyramidal cells, the dentate gyrus is made up of three layers of cells with granule 
cells representing the major cell type.  These cells have the ability to proliferate throughout 
the lifespan by means of neurogenesis.  This process is thought to be important for learning 
and memory (232).  Neurogenesis declines with age (233-235) and therefore, might be 
associated to cognitive impairments as demonstrated in various studies (236-238).  The 
defects in neurogenesis observed in these studies likely reflect changes in gene expression. 
The differences between the sub-regions within the hippocampus result in characteristic 
region-specific electrophysiological properties.  These arise from the fact that each field 
exhibits a specific synaptic response to plasticity-related genes normally expressed in all 
regions of the hippocampus (239,240).    
At the molecular level, each hippocampal sub-region has been shown to display unique 
transcription and protein expression patterns (241,242).  Additionally, analysis of the 
hippocampal regions in aged cognitively impaired animals compared to young and aged 
cognitively unimpaired animals revealed that changes in gene expression were more 
pronounced in the CA3 field than in the CA1 field and dentate gyrus of the hippocampus 
(243).  Similarly, in transgenic AD mice, the Schaffer collateral pathway (pathway from 
CA1 to CA3 field) of the hippocampus exhibits diminished LTP whereas the Mossy fibre 
pathway (from the dentate gyrus to the CA3 field) is slightly enhanced (244).  This 
supports a unique role for each sub-region within the hippocampus in learning and memory. 
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For all of the aforementioned reasons, qRT-PCR analyses must be performed separately in 
the cortex and sub-regions (dentate gyrus and CA1-CA3 fields) of the hippocampus in 
3xTg and WT mice and in the cortex and hippocampus of young and aged rats. 
 
  
2 Experimental procedures 
2.1 Animals 
Experiments were conducted in accordance with the guidelines of the Canadian 
Council of Animal care and were approved by the “Comité de déontologie de 
l’expérimentation sur les animaux (CDEA)” of “Université de Montréal”. 
2.1.1 Young and aged rats 
Four young (3 months) and four aged (24 months) Fisher 344 rats obtained from 
Harlan Laboratory were used for qPCR analysis.  Animals were euthanized in a CO2 
chamber one at a time and cortices and hippocampi were dissected within thirty minutes 
after death.  Dissection was performed under RNAse free conditions and tissues were 
maintained in cold Hank`s balanced salt solution (HBSS:  Potassium chloride 5.33 mM, 
potassium phosphate monobasic 0.441 mM, sodium chloride 137.93 mM, sodium 
phosphate dibasic anhydrous 0.338 mM, D-Glucose 5.56 mM, Phenol Red 0.0266 mM, 
sodium pyruvate 1 mM, Hepes 10 mM).  Once dissected, tissues were immediately placed 
in Trizol Reagent (Invitrogen) and kept on ice.  Tissues were then homogenized using a 
polytron and immediately subjected to RNA isolation or stored at -800C until use. 
2.1.2 3xTgmice and WT mice 
The hippocampi, dentate gyrus, and cortices of the right brain hemisphere of three 
transgenic Alzheimer (3xTg) mice and three control wild-type (WT) mice were obtained 
from Karl Fernandes laboratory in the “départment de pathologie et biologie cellulaire à 
l’Université de Montréal”.  The generation of 3xTg mice has been described previously 
(245).  Briefly, 3xTg mice were produced from co-microinjection of two independent 
transgenes encoding human APPswe and human tauP301L into single-cell embryos harvested 
from homozygous mutant PS1M146V knock-in mice.  The APPswe and tauP301L transgenes are 
both under the control of the neuron-specific mouse Thy1.2 regulatory element.  The non-
transgenic WT mice used have the same background as the 3xTg mice (C57BL6/129SVJ) 
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and were littermates of the original PS1M146V knock-in mice.  Housing conditions were 
identical for 3xTg and WT mice.   
The brain tissues (Hippocampus (CA1-CA3 fields), dentate gyrus, and cortex) of 
each of the 3xTg and WT mice were dissected from the brains of the mice once they had 
reached seven months of age.  At this age, cognitive impairments started to be apparent in 
the 3xTg mice.  Immediately after dissection, the brain tissues were stored at -800C.  Upon 
reception, the frozen tissues were deposited in Trizol Reagent (Invitrogen) and 
homogenized using a polytron.  RNA isolation was performed immediately afterwards or 
stored at -800C until use. 
 
2.2 RNA isolation 
All tissue samples were homogenized with a polytron in Trizol Reagent (Invitrogen), 
according to the protocol of the manufacturers.  RNA concentration was determined using 
DO readings at 260 nm and 280 nm in a spectrophotometer (Thermo Fisher Scientific).   
RNA samples were diluted in DEPC water (RNAse free water) to obtain a uniform 
concentration of 250 ng/µL across samples.  The quality of the RNA dilutions was 
determined with 1% agarose gel electrophoresis.  Samples were subjected to reverse 
transcription (RT) or kept at -800C until additional analysis.     
 
2.3 Quantitative PCR 
Prior to qPCR reactions, synthesis of cDNA was achieved using the GeneAmp RNA 
PCR kit (Applied Biosystems) following the guidelines of the manufacturer.  For the cortex 
and hippocampus samples of young and aged rats and for the cortex samples of WT and 
3xTg mice, the starting concentration of RNA used for cDNA synthesis was 750 ng/µL and 
for the dentage gyrus and hippocampus samples of WT and 3xTg mice the starting 
concentration of RNA was 200 ng/µL.  Subsequently, qPCR reactions were performed 
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using the LightCycler 480 SYBR Green I Master.  For each reaction, 3 µL of cDNA was 
added to a mix containing 3 µL PCR-grade water, 2 µL of 10X PCR primers, and                
10 µL of 2X SYBR Green Master Mix (Roche) for a total of 20 µL to obtain a                  
final concentration of 1X for the PCR primers and SYBR Green Master Mix.                   
Primers were designed using Integrated DNA Technology Primer Quest 
(http://www.idtdna.com/Scitools/Applications/Primerquest/), blasted using NCBI Primer-
Blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and synthesized at Integrated DNA 
Technology.  Primer sequences are listed in Table I and Table II.  Cycling conditions were 
5 min at 950C, followed by 50 cycles of 10 s at 950C, 20 s at 600C, and 30 s at 720C.  A 
melting curve followed the cycling conditions for identification of the specificity of the 
amplified products by fluorescence measurement every 10C from 720C to 950C. 
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Table I Sequence information of the rattus norvegicus primer pairs for use in 
quantitative real-time PCR 
Gene Primer Sequence 
AldolaseC Forward 5’-AACCTCAATGCCATCAACCGATGC-3’ 
Reverse 5’-TCATCTCGGCCCGCTTGATAAACT-3’ 
AGO2 Forward 5’-TCAGCCAGGGATCACATTCATCGT-3’ 
Reverse 5’-AGTCAAACTCAGTTGGGTGGGTGA-3’ 
Arc Forward 5’-AGAGCTGAAGGTGAAGACAAGCCA-3’ 
Reverse 5’-ACCTTAAGGCTCCTGCAAGGTTCT-3’ 
BDNF Forward 5’-AGGGCAGTTGGACAGTCATTGGTA-3’ 
Reverse 5’-TTCAACTCTCATCCACCTTGGCGA-3’ 
αCaMKII Forward 5’-AACACCAAGAAGCTCTCAGCCAGA-3’ 
Reverse 5’-ACTGTAATACTCCCGGGCCACAAT-3’ 
CPEB Forward 5’-TGACACAGATGCCTACACTTGGGT-3’ 
Reverse 5’-AAGGCACTGTATGGCAACTGCAAG-3’ 
CREB Forward 5’-AAATGACAGTTCAAGCCCAGCCAC-3’ 
Reverse 5’-TGCACTAAGGTTACAGTGGGAGCA-3’ 
FMRP Forward 5’-AGGCAGTTGGTGCCTTCTCTGTAA-3’ 
Reverse 5’-AGCTGCCTTGAACTCTCCAGTTGT-3’ 
MAP1B Forward 5’-TCCCAGACCACAGCGATTCATTCT-3’ 
Reverse 5’-ACAGGCTTCGTCCTTCCTGTTCTT-3’ 
MAP2 Forward 5’-GCAGCGCCAATGGATTTCCATACA-3’ 
Reverse 5’-TCCGTTGATCCCGTTCTCTTTGGT-3’ 
NMDAR1 Forward 5’-TGAGGCTTCACAGAAGTGCGATCT-3’ 
Reverse 5’-TCGCATTCCTGATACCGAACCCAT-3’ 
Pkcz Forward 5’-ACTATGGCCTGGACAACTTCGACA-3’ 
Reverse 5’-AGACAGCAGAAGCGGGTTGATGTA-3’ 
Stau1 Forward 5’-TGCACTGTGCGTGAAACTGGAAAG-3’ 
Reverse 5’-ATTAAACTGCTGTCCTCCCACGGA-3’ 
Stau2 Forward 5’-GGCAATGAAGTTGCGACTGGAACA-3’ 
Reverse 5’-AGGCTTTGGACCACTCCATCCTTT-3’ 
Trkβ Forward 5’-TTCCGAGGTTGGAACCTAACAGCA-3’ 
Reverse 5’-TTGCCGTTCTTCAGAAACGCCTTG-3’ 
32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table II Sequence information of the mus musculus primer pairs for use in 
quantitative real-time PCR 
 
Gene Primer Sequence 
AldolaseC Forward 5’- GGCCTAGCAATGCACATCCCATTT-3’ 
Reverse 5’-TGAGATGTGAGATGACTTGGCGCT-3’ 
AGO2 Forward 5’-AGGACAGCATGCTCTTTGAGACCT-3’ 
Reverse 5’-TGACAAAGGCCACACGGAACTAGA-3’ 
Arc Forward 5’-TGCCTACATGGGTTCCAAGACACT -3’ 
Reverse 5’-TGGCTTGTCTTCACCTTCAGCTCT-3’ 
BDNF Forward 5’- CACAGACGGCTCCTGCCAATTTAT-3’ 
Reverse 5’-TTTCTGATGCTCAGGAACCCAGGA-3’ 
αCaMKII Forward 5’-ACACACTCACACCACTTCCTTCCA-3’ 
Reverse 5’-TCCATACAAGAGCCAAACCCAGGA-3’ 
CPEB Forward 5’-TGACACAGATGCCTACACTTGGGT -3’ 
Reverse 5’-GGCAACTGCAGAATGAACGAACCA-3’ 
CREB1 Forward 5’-GGAATCTGGAGCAGACAACC -3’ 
Reverse 5’-ATAACGCCATGGACCTGGAC -3’ 
CycA Forward 5’-TACCTGCCTTCACTCATTGCTGGA-3’ 
Reverse 5’-ATTGACTGTTGGGCATGTTGTGGC-3’ 
FMRP Forward 5’-ATCAAGCTGGAGGTGCCAGAAGAT-3’ 
Reverse 5’-ATGTCAATCAACATGTGGGCTCGC-3’ 
GAPDH Forward 5’-TCAACAGCAACTCCCACTCTTCCA-3’ 
Reverse 5’-ACCCTGTTGCTGTAGCCGTATTCA-3’ 
MAP1B Forward 5’-TACCGTGAAAGTTGAGTCCGTGCT-3’ 
Reverse 5’-AGCAAACTGGGTGCTAGGGTACTT-3’ 
MAP2 Forward 5’-ATCCTGGTGCCCAGTGAGAAGAAA-3’ 
Reverse 5’-AGGTCCGGCAGTGGTTGGTTAATA-3’ 
NMDAR1 Forward 5’-GGAGCGGGTAAACAACAGCAACAA-3’ 
Reverse 5’-AATGGTCAGGCCCTGGTACTTGAA-3’ 
Pkcz Forward 5’-TGCCAGGTTCTATGCTGCTGAGAT-3’ 
Reverse 5’-TAATGTGTCCGTCGGCATCAAGGA-3’ 
Stau1 Forward 5’-CACAGCCAATTCTCATGCTGGCTT-3’ 
Reverse 5’-TCATGTGCAGTAGGAAGCACTGGT-3’ 
Stau2 Forward 5’-TCAGATCCAGCAAGCCAGAAAGGA-3’ 
Reverse 5’-TGTTCCAGTCGCAACTTCATTGCC-3’ 
Trkβ Forward 5’-ATGTTGCTGACCAAAGCAATCGGG-3’ 
Reverse 5’-GCCAAACTTGGAATGTCTCGCCAA-3’ 
Ywhaz Forward 5’-GTGCTTCCAAGTCGCTGTTGGTTT-3’ 
Reverse 5’-CATGGCCACCAAGTTGGAATGGTT-3’ 
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Standard curves were calculated from cDNA stock solutions for each primer pair tested 
for the chosen target and control genes (non-diluted, 10-1; 10-2; 10-3 and 10-4).  Triplicates 
were performed in each case.  To obtain the relative expression of target genes in the 
hippocampi and cortices of young and aged rats and in the hippocampi (CA1-CA3 fields), 
dentate gyrus, and cortices of WT and 3xTg mice, corresponding Ct values were obtained 
from duplicates and normalized according to the chosen control genes stably expressed in 
the brain (Aldolase C for young and aged rats, and aldolase C, Ywhaz (246) and GAPDH 
(246) for 3xTg and WT mice).  The mean relative expression of 13 target genes was 
calculated for 2 groups where group 1 refers to young rats and group 2 refers to aged rats 
and was calculated separately for the two subgroups.  These subgroups consist of different 
areas of the brain including the cortex and the hippocampus.   
Similarly, the mean relative expression of 14 genes was calculated for a third and 
fourth group referring to WT mice and 3xTg mice, respectively.  In this case, the 
calculations were performed separately for three subgroups consisting of different brain 
regions including the cortex, the hippocampus CA1-CA3 fields), and the dentate gyrus.  
Statistics were performed using the ‘R’ program.   
Normalized data were tested for mean differences using the Welch two sample student 
t-test.  More specifically, the mean difference in mRNA expression was compared for 
group 1 and group 2 for each subgroup described and for group 3 and group 4 for each 
subgroup described.  All data are presented as the mean ± standard error, which is indicated 
by bars in the figures and a value of p < 0.05 was considered to be significant.  
  
3 Results 
To study the expression of genes related to synaptic function and memory processes in 
aging and AD, we performed qRT-PCR analyses.  For AD, the mice used were 7-month old 
3xTg transgenic mice that demonstrated impaired working memory performance compared 
with nontransgenic littermates (245).  Analyses were performed in three different brain 
regions including the cortex, hippocampus (CA1-CA3 fields), and dentate gyrus.  In order 
to evaluate age-related cognitive decline, 3-month and 24-month old Fisher 344 rats were 
compared.  Analyses were performed in the cortex and hippocampus of these rats.  
Several plasticity-related genes could become disrupted during aging and AD including 
genes involved in cytoskeletal integrity, microtubule-dependent transport, synaptic 
functions, and neurotransmission.  This could contribute to alterations in neuronal structure 
that are associated with age-related cognitive decline and AD.  For this reason, fourteen 
different genes involved in the various processes of synaptic plasticity were chosen for 
investigation (Arc, AGO2, BDNF, αCaMKII, CPEB, CREB1, FMRP, MAP1B, MAP2, 
NMDAR1, Pkcz, Stau1, Stau2, and Trkβ).  
The expression of the mRNAs studied was normalized using three different 
reference genes (Aldolase C, Ywhaz, and GAPDH) in AD for improved data normalization.  
On the other hand, only aldolase C was used for normalization in young and aged rats.  
Initially, the expression level of these genes and various other potential candidate reference 
genes including, β-actin, CycA, synaptophysin, and calnexin were tested for their stable 
expression in the brains of aged rats and 3xTg mice compared to young rats and WT mice, 
respectively.  The three control genes chosen were the ones with the most stable expression 
across individuals and with relevant supporting literature for their use as reference genes in 
aging and AD.   
Aldolase C is a glycolytic enzyme expressed at high levels in the adult brain (247) 
with a predominant expression in neuronal cells (248,249) as is the case for many of the 
genes under investigation such as Arc (250), BDNF (251) and its receptor Trkβ (252), 
FMRP (253), and αCaMKII (254).  The expression of aldolase C was found to be stable in 
aged rats compared to young rats (2).  Additionally, it is a neuronal gene that contains a 
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housekeeping-like promoter (255), and it has not been reported to participate in synaptic 
plasticity and/or in the progression of cognitive decline and AD. This helps support the 
notion that it is a good reference gene for the conditions studied.  
As for Ywhaz and GAPDH, they were used in conjunction with aldolase C since they 
are expressed in both neuronal and non-neuronal cells.  Despite the fact that all genes under 
investigation are expressed in neuronal cells, it is possible that they are equally expressed in 
non-neuronal cells (ex:  MAP1B (256), MAP2 (257), Pkcz (258), Stau1, and Stau2 (82) and 
may even become overexpressed in glial cells such as astrocytes (ex: CREB (259) under 
conditions of excitotoxically damaged hippocampi as can be seen in AD (260).  In addition, 
Ywhaz and GAPDH are both housekeeping genes that have been validated by geNorm 
application as two of the most stable genes in AD (246) thereby, making them suitable to 
use as reference genes.   
 
3.1 Expression profile of plasticity-related genes in different brain 
regions of 3xTg mice and WT mice 
3.1.1 Hippocampus: CA1-CA3 fields 
The expression of plasticity-related genes was first studied in the hippocampus 
(CA1-CA3 fields) using aldolase C as a reference gene.  Results from the qRT-PCR 
analysis revealed a significant increase in the expression of four of the genes studied in 
3xTg mice compared to WT mice.  These genes were BDNF (p = 0.0104), CREB1 (p = 
0.0228), MAP1B (p = 0.0084), and Stau2 (p = 0.0370) (Table III).  BDNF and CREB1 both 
participate predominantly in the induction and maintenance of LTP by promoting synthesis 
of new NMDA receptors (45,46) and increasing the conductance (43,44) through these 
receptors and by activating the transcription of plasticity-related genes (58), respectively.  
Stau2 and MAP1B on the other hand, participate mainly in LTD maintenance.  More 
precisely, Stau2 regulates the transport and possibly the translation of MAP1B (88); a 
protein critical for the maintenance of cytoskeletal integrity (73).  The expression of the 
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other genes investigated did not change significantly between groups (p > 0.05).  The 
normalized differential expression of all genes investigated in the hippocampus (CA1-CA3 
fields) of 3xTg and WT mice is depicted in figure 7.    
 
mRNA Hippocampus 
t-value p-value 
Arc -1.9181 0.1951 
AGO2 -1.4905 0.2653 
BDNF -5.0001 0.0104 
αCamKII -2.1880 0.0975 
CPEB -2.9104 0.0584 
CREB1 -4.6123 0.0228 
FMRP -2.1607 0.0969 
MAP1B -6.9121 0.0084 
MAP2 -0.0028 0.9980 
NMDAR1 0.0055 0.9959 
Pkcz -0.5477 0.6139 
Stau1 -0.0101 0.9927 
Stau2 -3.1004 0.0370 
Trkβ 0.2818 0.7921 
 
Table III  p-value: Statistical significance in the hippocampus (CA1-CA3 fields) of 
3xTg and WT mice relative to aldolase C. p-value obtained from Welch Two Sample t-
test to determine the significance of the difference between the expression levels of 
plasticity-related mRNAs in the hippocampus (CA1-CA3 fields) of 3xTg and WT mice 
relative to aldolase C (Significant difference if p < 0.05 highlighted in yellow). 
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Figure 7  Normalized expression level of mRNAs in the hippocampus (CA1-CA3 
fields) of 3xTg and WT mice (reference gene: Aldolase C). Significant increases were 
observed for the expression of BDNF, CREB1, MAP1B, and Stau2 mRNAs (p < 0.05).  No 
significant differences were found in the expression of the other genes under investigation 
(p > 0.05).    
qRT-PCR experiments were repeated using Ywhaz as a reference gene.  Upon 
analysis of results, a significant increase (Table IV) was observed for the expression of 
BDNF (p = 0.0222) and  MAP1B (p = 0.0171) mRNAs in the hippocampus of 3xTg mice 
compared to their WT counterpart but not for the expression of Stau2 and CREB1 mRNAs 
as observed for the first set of qRT-PCR performed using aldolase C as the reference gene.  
The expression of the other genes studied did not differ significantly between groups (p > 
0.05).  The normalized expression between 3xTg mice and WT mice for all genes is 
demonstrated in figure 8.  
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mRNA Hippocampus 
t-value p-value 
Arc -1.5273 0.2226 
AGO2 .0.9751 0.3869 
BDNF -3.7141 0.0222 
αCamKII 0.7114 0.5487 
CPEB -1.0244 0.3716 
CREB1 -2.9384 0.0927 
FMRP -1.2774 0.3035 
MAP1B -5.0235 0.0171 
MAP2 1.0375 0.3926 
NMDAR1 2.4112 0.0798 
Pkcz 1.2563 0.3235 
Stau1 0.3359 0.7580 
Stau2 -1.1944 0.3014 
Trkβ 1.5948 0.2419 
 
Table IV  p-value: Statistical significance in the hippocampus (CA1-CA3 fields) of 
3xTg and WT mice relative to Ywhaz. p-value obtained from Welch Two Sample t-test to 
determine the significance of the difference between the expression levels of plasticity-
related mRNAs in the hippocampus (CA1-CA3 fields) of 3xTg and WT mice relative to 
Ywhaz (Significant difference if p < 0.05 highlighted in yellow). 
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Figure 8  Normalized expression level of mRNAs in the hippocampus (CA1-CA3 
fields) of 3xTg and WT mice (reference gene: Ywhaz). Significant increases were 
observed for the expression of BDNF and MAP1B mRNAs (p < 0.05).  No significant 
differences were found in the expression of the other genes under investigation (p > 0.05).    
 
Finally, the same experiment was performed using a third reference gene; GAPDH.  
qRT-PCR experiments were performed on 13 selected genes.  The expression for MAP1B 
mRNA increased significantly (p = 0.0331) in 3xTG mice compared to WT mice (Table V)  
as observed for both previous sets of qRT-PCR experiments using aldolase C and Ywhaz as 
reference genes. The expression of Stau2 mRNA also increased significantly (p = 0.0127) 
similarly to the first experiment using aldolase C as a reference gene.  Lastly, AGO2 
mRNA expression was significantly increased (p = 0.0475) in 3xTg mice compared to WT 
mice.  AGO2 protein has a fundamental role in RNA silencing processes (261) which is 
important in regulating the expression of genes involved in synaptic plasticity for memory 
and learning (134-137).  The expression of the other plasticity-related genes tested in the 
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hippocampus did not change significantly between the groups being compared (p > 0.05) 
(figure 9).  However, it must be noted that BDNF mRNA expression increased 
considerably, similar to previous experiments using aldolase C and Ywhaz as reference 
genes.  In this case, the p-value for BDNF was calculated at p = 0.0559 which is very close 
to the cut-off value of p < 0.05 for a significant difference between groups.  
  
mRNA Hippocampus 
t-value p-value 
Arc -1.6289 0.2263 
AGO2 -3.6075 0.0475 
BDNF -2.6879 0.0559 
αCamKII -1.2271 0.2895 
CPEB -1.8037 0.1524 
FMRP -0.8197 0.4619 
MAP1B -4.0154 0.0331 
MAP2 1.0474 0.3873 
NMDAR1 1.3829 0.2926 
Pkcz 0.6849 0.5333 
Stau1 -1.7055 0.2082 
Stau2 -4.3220 0.0127 
Trkβ 1.9484 0.1298 
 
Table V p-value: Statistical significance in the hippocampus (CA1-CA3 fields) of 3xTg 
and WT mice relative to GAPDH.  p-value obtained from Welch Two Sample t-test to 
determine the significance of the difference between the expression levels of plasticity-
related mRNAs in the hippocampus (CA1-CA3 fields) of 3xTg and WT mice relative to 
GAPDH (Significant difference if p < 0.05 highlighted in yellow). 
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Figure 9  Normalized expression level of mRNAs in the hippocampus (CA1-CA3 
fields) of 3xTg and WT mice (reference gene: GAPDH). Significant increases were 
observed for the expressions of AGO2, MAP1B, and Stau2 mRNAs (p < 0.05).  No 
significant differences were found in the expression of the other genes under investigation 
(p > 0.05).    
 
3.1.2 Hippocampus: Dentate gyrus 
Results from the qRT-PCR experiments using aldolase C as a reference gene 
revealed a significant increase in  the expression of MAP1B mRNA (p = 0.0313) in the 
dentate gyrus of 3xTg mice compared to WT mice (Table VI) as observed in the 
hippocampus (CA1-CA3 fields) for all reference genes used.  However, the expression of 
the other genes studied did not display a significant change between groups (p > 0.05) 
(figure 10). 
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mRNA Dentate gyrus 
t-value p-value 
Arc -1.0451 0.3947 
AGO2 0.3113 0.7759 
BDNF 1.0170 0.3988 
αCamKII 1.2120 0.3282 
CPEB 2.5026 0.0876 
CREB1 0.1668 0.8785 
FMRP 1.0284 0.3660 
MAP1B -3.7822 0.0313 
MAP2 0.8221 0.4621 
NMDAR1 0.5964 0.5987 
Pkcz 1.2553 0.3161 
Stau1 1.2338 0.3226 
Stau2 -0.2493 0.8190 
Trkβ -0.5090 0.6559 
 
Table VI  p-value: Statistical significance in the dentate gyrus of 3xTg and WT mice 
relative to aldolase C.  p-value obtained from Welch Two Sample t-test to determine the 
significance of the difference between the expression levels of plasticity-related mRNAs in 
the dentate gyrus of 3xTg and WT mice relative to aldolase C (Significant difference if p < 
0.05 highlighted in yellow). 
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Figure 10  Normalized expression level of mRNAs in the dentate gyrus of 3xTg and 
WT mice (reference gene: Aldolase C). A significant increase was observed for the 
expression of MAP1B mRNA (p < 0.05).  No significant differences were found in the 
expression of the other genes under investigation (p > 0.05).    
 
In summary, the expression of the genes investigated varied across the sub-regions 
of the hippocampus with the exception of MAP1B.  MAP1B mRNA expression increased 
significantly in the hippocampus (CA1-CA3 fields) and the dentate gyrus of 3xTg mice 
compared to WT mice, for all reference genes used.  As for Stau2 and BDNF, their mRNA 
expressions increased significantly in the CA1-CA3 fields of the hippocampus of 3xTg 
mice compared to WT mice for two out of three reference genes used.  Lastly, AGO2 and 
CREB1 mRNA expression increased significantly in the hippocampus (CA1-CA3 fields) of 
3xTg mice compared to WT mice for only one of the reference genes used.  This 
demonstrates how different sub-regions of the same tissue can express different genes in 
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order to behave as separate units and to generate a specific response upon a synaptic 
stimulation (239,240).       
 
3.1.3 Cortex 
To determine whether the expression of genes is affected to a lesser extent in the 
cortex compared to the hippocampus at the onset of AD and if different genes become 
dysregulated, we performed qRT-PCR experiments in the cortex of 3xTg and WT mice.  
The results normalized using aldolase C demonstrated a significant increase in the 
expression of MAP1B mRNA (p = 0.0031) in 3xTg mice compared to WT mice (Table 
VII), similar to observations made for the hippocampus (CA1-CA3 fields) and dentate 
gyrus.  On the other hand, a significant decrease was observed for the expression of 
αCaMKII mRNA (p = 0.0147) in the cortex of 3xTg mice compared to WT mice.  CaMKII 
protein becomes activated upon synaptic stimulation and participates in increasing the 
conductance of AMPAR to facilitate a subsequent synaptic transmission for enhanced LTP 
(29,37-39).  The other genes investigated did not exhibit significant changes in their 
expression levels (p > 0.05) between the groups studied (Figure 11). 
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mRNA Cortex 
t-value p-value 
Arc -2.129 0.1328 
AGO2 0.0330 0.9759 
BDNF -1.4745 0.2148 
αCamKII 5.2226 0.0147 
CPEB 0.9796 0.3868 
CREB1 -0.3831 0.7363 
FMRP -2.0559 0.1092 
MAP1B -9.1744 0.0031 
MAP2 0.6320 0.5628 
NMDAR1 0.5265 0.6440 
Pkcz 0.1733 0.8730 
Stau1 -3.3046 0.0696 
Stau2 -0.0411 0.9701 
Trkβ -2.4305 0.0719 
 
Table VII p-value: Statistical significance in the cortex of 3xTg and WT mice relative 
to aldolase C. p-value obtained from Welch Two Sample t-test to determine the 
significance of the difference between the expression levels of plasticity-related mRNAs in 
the cortex of 3xTg and WT mice relative to aldolase C (Significant difference if p < 0.05 
highlighted in yellow). 
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Figure 11 Normalized expression level of mRNAs in the cortex of 3xTg and WT mice 
(reference gene: Aldolase C). A significant increase was observed for the expression of 
MAP1B mRNA (p < 0.05).  A significant decrease was observed for the expression of 
αCaMKII mRNA.  No significant differences were found in the expression of the other 
genes under investigation (p > 0.05).    
    
qRT-PCR experiments were repeated in the cortex of 3xTg and WT mice using 
Ywhaz  gene as a reference.  In this case, the expression of MAP1B mRNA increased 
significantly (p = 0.0008) in the cortex of 3xTg mice compared to WT mice (Table VIII) as 
observed when aldolase C was used as the reference gene.  However, results obtained for 
the expression of αCaMKII mRNA using aldolase C were not reproduced when using 
Ywhaz for normalization.  The expression of αCaMKII mRNA and of the other mRNAs 
under investigation remained relatively stable between groups (p > 0.05) (Figure 12). 
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mRNA Cortex 
t-value p-value 
Arc -2.1070 0.1342 
AGO2 0.1283 0.9052 
BDNF -2.6705 0.1083 
αCamKII 1.7411 0.1762 
CPEB 0.1351 0.8992 
CREB1 1.3911 0.2413 
FMRP -0.6429 0.5726 
MAP1B -9.1873 0.0008 
MAP2 0.9097 0.4145 
NMDAR1 0.7667 0.5158 
Pkcz 0.5612 0.6096 
Stau1 -1.4043 0.2334 
Stau2 0.4978 0.6551 
Trkβ -0.7969 0.4732 
 
Table VIII  p-value: Statistical significance in the cortex of 3xTg and WT mice 
relative to Ywhaz.   p-value obtained from Welch Two Sample t-test to determine the 
significance of the difference between the expression levels of plasticity-related mRNAs in 
the cortex of 3xTg and WT mice relative to Ywhaz (Significant difference if p < 0.05 
highlighted in yellow). 
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Figure 12 Normalized expression level of mRNAs in the cortex of 3xTg and WT mice 
(reference gene: Ywhaz). A significant increase was observed for the expression of 
MAP1B mRNA (p < 0.05).  No significant differences were found in the expression of the 
other genes under investigation (p > 0.05).    
 
Therefore, as observed for the dentate gyrus, only MAP1B mRNA expression 
increased significantly in the cortex of 3xTg mice compared to WT mice for the reference 
genes used.  This helps demonstrate the selective progression of AD whereby the 
hippocampus (CA1-CA3 fields) is most vulnerable at the onset of the disease followed by 
the cortex (203).   
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3.2 Expression profile of plasticity-related genes in the cortex and 
hippocampus of aged 24-month old rat and young 3-month old 
Fisher 344 rats 
3.2.1 Hippocampus 
To establish an age-related difference in expression levels of the plasticity-related 
mRNAs in the hippocampus of 24-month old rats compared to 3-month old rats, qRT-PCR 
experiments were performed using aldolase C as a reference gene.  No significant 
differences (p > 0.05) were observed in the expression level of the mRNAs studied between 
the two groups (Table IX).  The expression of all mRNAs is depicted in figure 13 for young 
rats compared to aged rats. 
 
 
 
 
 
 
 
 
Table IX p-value: Statistical significance in the hippocampus of young and aged 
Fisher 344 rats relative to aldolase C.  p-value obtained from Welch Two Sample t-test to 
determine the significance of the difference between the expression levels of plasticity-
related mRNAs in the hippocampus of young and aged Fischer 344 rats relative to aldolase 
C (Significant difference if p < 0.05 highlighted in yellow). 
mRNA Hippocampus 
t-value p-value 
Arc 0.4165 0.7034 
AGO2 1.2178 0.2696 
αCamKII 0.3954 0.7135 
CPEB -0.0507 0.9612 
CREB 0.1356 0.8968 
FMRP 0.3019 0.7736 
MAP1B -0.0757 0.9438 
MAP2 -0.5570 0.6058 
NMDAR1 0.3084 0.7761 
Pkcz -0.0130 0.9896 
Stau1 -0.2066 0.8464 
Stau2 1.4302 0.2087 
Trkβ 0.6393 0.5467 
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Figure 13 Normalized expression of mRNAs in the hippocampus of young and aged 
rats (reference gene: Aldolase C).  No significant differences were found in the 
expression of the genes under investigation (p > 0.05).    
 
3.2.2 Cortex 
The expression of the chosen plasticity-related mRNAs was also tested in the cortex 
of the young and aged rats using aldolase C as a reference gene.  Results from the qRT-
PCR experiments revealed a significant increase in CPEB mRNA in aged rats compared to 
the young rats (Table X).  The other genes investigated did not exhibit a significant 
difference in expression between groups (p > 0.05) (Figure 14). 
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mRNA Cortex 
t-value p-value 
Arc -1.6260 0.1959 
AGO2 -0.6602 0.5400 
αCaMKII -0.2073 0.8435 
CPEB -4.7760 0.0050 
CREB -0.2578 0.8071 
FMRP -1.4781 0.1929 
MAP1B -0.6931 0.5170 
MAP2 0.0871 0.9337 
NMDAR1 -0.450 0.6690 
Pkcz -0.9099 0.4169 
Stau1 -0.2693 0.8003 
Stau2 -0.3510 0.7384 
Trkβ -0.2063 0.8440 
 
Table X p-value: Statistical significance in the cortex of young and aged Fisher 344 
rats relative to aldolase C.  p-value obtained from Welch Two Sample t-test to determine 
the significance of the difference between the expression levels of plasticity-related 
mRNAs in the hippocampus of young and aged Fischer 344 rats relative to aldolase C 
(Significant difference if p < 0.05 highlighted in yellow). 
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Figure 14 Normalized expression of mRNAs in the cortex of young and aged rats 
(reference gene: Aldolase C).  A significant increase was found in the expression of CPEB 
mRNA (p < 0.05).  No significant differences were found in the expression of the other 
genes under investigation (p > 0.05).    
 
It has been established that the hippocampus is most vulnerable during aging (3).  
However, a significant increase in CPEB expression was only observed in the cortex of 
aged rats compared to young rats.  This might represent another example of the difference 
in gene expression across brain tissues.   
 
  
4 Discussion 
Age-related cognitive decline of varying severity is common amongst an otherwise 
healthy aging population but its causes remain to be determined.  It has been suggested that 
alterations in gene expression in the brain might underlie synaptic dysfunction that occurs 
during normal and pathological aging (262,263).  In this study we determined the 
expression profile of plasticity-related mRNAs in aging and in Alzheimer’s disease.   
 
4.1 Alzheimer’s disease 
AD is characterized by amyloid plaques and neurofibrillary tangles that promote the 
loss of neurons in areas of the brain involved in learning and memory.  However, cognitive 
and memory impairment precedes neurodegeneration and may even occur before excessive 
Aβ deposition (214).  Under normal conditions, physiological levels of Aβ are essential for 
synaptic plasticity and memory consolidation (264) whereas, under pathological conditions, 
toxic soluble oligomeric aggregates of Abeta accumulate and initiate synaptic dysfunction 
(265).  The current hypothesis suggests that cognitive decline and synapse loss in AD 
correlates with the levels of soluble Abeta rather than the number of amyloid plaques.  This 
new line of thinking emerged from observations that amyloid plaques also occur in 
individuals with no cognitive impairment (265,266).  Furthermore, senile plaque formation 
is now believed to occur in order to protect neurons from the toxicity of diffusible Abeta 
oligomers by sequestering them into deposits (267).  
Accumulation of soluble Aβ disrupts the molecular pathways that lead to LTP and/or 
LTD.    In fact, it has been demonstrated that Aβ oligomers inhibit LTP and induce LTD by 
disturbing molecular events and thus, causing gene expression changes in the brain (217).  
However, it remains to be elucidated which plasticity related genes become dysregulated in 
the presence of Alzheimer’s disease, especially at the onset of the disease.  For that reason, 
we investigated the expression levels of various plasticity related mRNAs in the brain of 
3xTg mice (C57BL6/129SVJ) compared to wild type mice at an early stage of Alzheimer’s 
disease when cognitive deficits are apparent especially in the hippocampus but without 
excessive neuron death (268).  
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4.1.1 LTD and plasticity-related mRNAs 
The results of the qRT-PCR study for Alzheimer’s disease revealed significant 
changes in the expression of specific plasticity-related mRNAs mainly involved in LTD.   
We observed a significant increase in MAP1B mRNA expression in Alzheimer mice 
compared to their WT counterpart in all brain regions including the cortex, hippocampus 
and dentate gyrus relative to all the control genes used.  This is in agreement with a study 
that demonstrated the upregulation of MAP1B mRNA in cultured cortical neurons upon 
addition of Aβ1-42 peptide (269).  This study also provided insight into the overexpression 
of MAP1B protein in cultured cortical neurons. MAP1B is a minor component of NFT and 
senile plaque neuritis in AD. Accordingly, the author speculated that aberrant neuritic 
sprouting processes are induced by the deposition of Aβ or plaque-associated molecules, 
such as MAP1B, at an early stage of AD before neurodegeneration.  To test this hypothesis, 
an in vitro transfection experiment of the MAP1B gene was performed and successively 
revealed that up-regulation of MAP1B did in fact accelerate disease progression by 
promoting neurite outgrowth and subsequently, neuronal death.   
Conversely, a different study observed diminished expression of MAP1B mRNA in 
the temporal lobe and occipital lobe of AD brain (270).  In the same experiment, levels of 
MAP2 mRNA were found to be up-regulated in the AD occipital lobe.  Both, MAP1B and 
MAP2 become sequestered by hyperphosphorylated tau which leads to disassembly of 
microtubules in AD.  This results in the breakdown of the neuronal microtubule network.  
Based on their findings, the authors speculated that the increase in MAP2 served to 
compensate for the decreased expression of MAP1B to help protect the occipital lobe 
against cell death during early stages of neurodegeneration in AD.  These results are 
contrary to our observations, where no significant difference was observed in the mRNA 
expression of MAP2 in AD compared to WT mice.  The discrepancy between results for 
MAP1B and MAP2 mRNA expression could be explained by the fact that we used mice 
with early stage AD for our experiments, whereas they used brain samples from one human 
patient with moderate disease stage.  It is therefore possible that MAP1B mRNA increases 
in the initial stages of AD and decreases thereafter.   
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Interestingly, a study demonstrated an Aβ-dependent activation of caspase-3 and 
calpain which led to proteolysis of MAP1B (271).  Another study demonstrated that Aβ1-
42 colocalizes with MAP1B and binds to its N-terminal region in SH-SY5Y human 
neuroblastoma cells (272).  This could explain how the microtubule network becomes 
disrupted in the early stages of AD preceding caspase activation and neurodegeneration.  A 
possible mechanism is that Aβ1-42 initially binds to MAP1B causing its dissociation from 
microtubules and in this manner disturbs the cytoskeletal network.  Meanwhile, caspase-3 
and calpain become activated in an Aβ-dependent manner and target the dissociated 
MAP1B for degradation.  This could help explain how MAP1B mRNA initially increases 
at the onset of AD but becomes diminished as the disease progresses when proteolysis 
starts dominating synthesis.    
It is logical to assume that as a result of an increase in MAP1B mRNA, the 
expression of associated regulatory RNA binding proteins must increase accordingly.  
Indeed, the expression of the mRNA coding for Stau2, a protein involved in regulating the 
transport of specific mRNAs including MAP1B (88), appears to increase significantly in 
the hippocampus of AD mice compared to WT mice when both aldolase C and GAPDH are 
used as control genes.  An increase in Stau2 mRNA might lead to increased translation of 
Stau2 protein and in this manner bring about enhanced transport of MAP1B mRNA.  Under 
normal conditions, both, Stau2 and MAP1B proteins mainly participate in LTD 
maintenance and so their translation is enhanced upon LTD induction (88,109).  It has been 
demonstrated that LTD starts to prevail over LTP in AD due to internalization of AMPAR 
(219,220) and decreased current through NMDAR (218).  The resulting diminished calcium 
entry into the postsynaptic neuron triggers the induction of LTD rather than LTP (216,217) 
which only occurs in the presence of high calcium concentration (1).  It is therefore not 
surprising to observe an increase in the expression levels of Stau2 and MAP1B mRNAs in 
AD since low calcium concentrations activate LTD-related mRNAs that participate in 
promoting LTD maintenance.  
Two other molecules, Arc and FMRP, involved in LTD maintenance (101,102,105) 
showed a tendency to increase in the cortex and hippocampus of AD mice compared to WT 
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mice for all control genes used.  However, the differences observed were not significant 
mostly due to expression variations between mice belonging to the same group.  Further 
studies should be conducted using a greater sample size to determine if a significant 
increase truly exists for these mRNAs in AD mice compared to WT mice.  In our study, the 
tendency of Arc mRNA to increase is in disagreement with studies that demonstrated a 
decrease in Arc mRNA levels in the neocortex and hippocampus of aged APP transgenic 
mice (273) and in the cortex and hippocampus of aged APP + PS1 transgenic mice (274).  
Both these studies performed RT-qPCR experiments in aged transgenic mice between 25 to 
30 months old and 17 to 18 months old, respectively, whereas our experiments were 
performed in 7 month old transgenic mice.  It is therefore possible that an initial increase in 
Arc mRNA occurs in AD before the disease progresses and neurodegeneration worsens at 
which point the expression levels of Arc mRNA might drop considerably.    
As for FMRP, no studies have been published on its expression level in AD.  
Nevertheless, it has been demonstrated that FMRP supresses the translation of APP mRNA 
(112).  Therefore, in the absence of FMRP, APP translation is increased and thus, impacts 
the levels of processed Aβ.  Enhanced processing of APP via decreased translational 
repression by FMRP is a plausible mechanism by which increased Aβ deposition occurs in 
AD.  However, our results suggest that FMRP mRNA increases in AD.  The increase in 
FMRP mRNA might represent a compensatory mechanism at the onset of AD to increase 
FMRP translation and thereby increase the translational repression of APP.  This would 
help prevent excessive processing of APP.  This could also be true for MAP1B.  Under 
normal conditions, FMRP binds to and inhibits MAP1B mRNA (275,276).  Therefore an 
increase in FMRP mRNA might correlate with the increase in MAP1B mRNA that we 
observed at the onset of AD.  Similar to the case of APP, increased FMRP mRNA possibly 
serves as a compensatory mechanism to help inhibit overexpression of MAP1B mRNA.  
However, it is also possible that despite an increase in its mRNA expression level, the 
protein expression level of FMRP protein is decreased or its function is altered.  
Interestingly, altered FMRP expression and/or function would cause the compensatory 
mechanisms to fail and consequently, AD would continue to progress.  Indeed, an example 
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of altered FMRP function comes from a study in which the absence of AGO2 prevents 
FMRP repression of APP translation (112).  AGO2 colocalizes with FMRP (277) and it is 
an argonaute protein that is a component of the miRISC involved in the processing and 
regulation of miRNAs (134,135).  
In fact, FMRP also associates with endogenous miRNAs for the precise 
translational repression of specific mRNAs (112).  If the association between these 
molecules is altered, the translational regulation via FMRP becomes dysfunctional.  For 
example, we observed that the expression of AGO2 increased significantly in the 
hippocampus of AD mice when GAPDH was used as the control gene.  Such an alteration 
in mRNA expression could have an impact on FMRP function itself by altering 
associations between molecules.  It is also possible that the miRNAs with which FMRP 
associates regulate the translation of FMRP mRNA itself.  In this case, an imbalance in 
miRNA expression could inhibit translation of FMRP thereby, explaining the increased 
expression of FMRP mRNA observed in our experiments and the expected decrease in its 
protein level.   
Altogether, these observations demonstrate the detrimental effects of Aβ on the 
expression of specific plasticity-related mRNAs mainly involved in LTD.  These effects 
can also be observed for mRNAs mainly involved in LTP.  This further contributes to the 
disruption of synaptic plasticity and as a consequence, to the progression of AD. 
 
4.1.2 LTP and plasticity-related mRNAs 
For LTP, functional NMDA and AMPA receptors are crucial in propagating a 
synaptic transmission to activate the transcription of LTP-related mRNAs.  However, 
increasing evidence suggests that Aβ synaptic dysfunction is attributed to the synaptic 
removal of AMPA receptors (220,278,279).  In a study led by Zhenglin Gu, CaMKII, a 
molecule essential for trafficking of AMPAR at synapses (280,281), was found to be 
reduced at synapses by Aβ whereas it was found to be increased in the cytosol of cortical 
neurons from APP transgenic mice (282).  The decrease of CaMKII at synapses led to the 
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loss of synaptic AMPA receptors.  The authors speculated that Aβ might disturb the 
synaptic distribution of CaMKII by altering intracellular calcium signalling and/or actin 
cytoskeleton dynamics.  These events are required for the synaptic translocation of 
CaMKII.  In our study, we wanted to test the possibility that Aβ might interfere with the 
transcription of αCaMKII which could also lead to decreased synaptic pools of CaMKII.  
However, we failed to observe a significant difference in the expression level αCaMKII in 
most brain tissues and for all the control genes used with the exception of one.  αCaMKII 
was significantly reduced in the cortex of Alzheimer mice compared to WT mice when 
aldolase C  was used as the control gene.  In light of these results, it might be more likely 
that defects occur in the transport and/or translation of the αCaMKII mRNA transcript 
which would be consistent with the previous findings that Aβ alters CaMKII 
compartmentalization rather than its transcription. 
In addition, the same study (282) failed to observe a change in the synaptic 
expression of NMDAR.  Consistent with these results, we found no significant change in 
the mRNA expression level of NMDAR1 in Alzheimer mice compared to WT mice for all 
conditions.  Normal NMDAR mRNA expression is crucial in ensuring optimal translation 
of synaptic NMDAR.  This information further suggests that it is predominantly the activity 
of NMDAR that is altered at the onset of Alzheimer’s disease (218) rather than its 
transcription and/or translation.  However, it is also possible that the loss of synaptic 
AMPAR precedes that of NMDAR.  Changes in the transcription and/or translation of 
NMDAR might occur at a later stage of the disease.  In fact, altered calcium homeostasis 
due to reduced NMDAR activity eventually causes the activation of calcineurin which 
promotes the internalization of NMDA receptors (219).  Removal of NMDA receptors from 
the synaptic membrane also occurs via oligomeric Aβ-dependent dephosphorylation of 
NR2B subunits (221).  These events likely start occurring at a more advanced stage of 
Alzheimer’s disease which would explain why no differences in mRNA expression levels 
of NMDAR are observed in the initial stages of AD.  This could also be true for the 
expression of Stau1, Pkcz, and CPEB mRNAs for which no significant differences were 
observed in 3xTg mice compared to WT mice. It would be interesting to repeat these 
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experiments at various stages of the disease to establish when and how expression 
alterations occur.   
Dysfunction in NMDAR activity causes decreased current through this receptor and 
results in a disruption in the molecular chain of events that occur downstream of synaptic 
stimulation via NMDAR such as CREB activation via MAPK (222).  For example, it has 
been well established that the activity of CREB is reduced in Alzheimer’s disease.  It has 
also been suggested that CREB mRNA and protein expression levels decrease in the 
presence of Aβ (223).  These findings are inconsistent with our results which suggest a 
significant increase in CREB mRNA expression in the hippocampus of Alzheimer mice 
compared to WT mice when aldolase C is used as the control gene.  Although not 
significant, this tendency is also observed when Ywhaz is used as the control gene.  The 
discrepancy between results obtained could be explained by the fact that we used 
hippocampal extracts from transgenic Alzheimer mice whereas Pugazhenthi S et al. used 
cultured rat hippocampal neurons to test the effects of Aβ on CREB mRNA expression.  
Although an increase in CREB mRNA expression is unexpected, it could represent a 
compensatory mechanism at the onset of Alzheimer’s disease to increase the protein level 
of CREB and subsequently, its activity in order to restore normal LTP.  
Normal CREB activity via phosphorylation is crucial in regulating the transcription 
of CREB specific plasticity-related genes such as BDNF (283).  It is logical to assume that 
the expression of these genes correlates with the expression and activity of CREB.  Indeed, 
in our study, we observed an increase in the CREB target gene BDNF in the hippocampus 
of Alzheimer mice compared to WT mice when either Ywhaz or aldolase C are used as the 
control gene. This is consistent with the increase we previously observed for CREB1 
mRNA in the early stages of AD.  Similar observations were made in a study in which 
differentiated SH-SY5Y cells treated with Abeta caused up-regulation of BDNF as well as 
its receptor Trkβ (284).  On the other hand, various other studies report a decrease in the 
mRNA (285-288) and protein (289-291) levels of BDNF in the hippocampus and neocortex 
of post-mortem samples from AD patients.  This observation was also observed for the 
receptor Trkβ (289,292).  These conflicting results could be explained by the varying 
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severity of Alzheimer’s disease in the different studies.  The studies demonstrating a 
decrease in BDNF mRNA and protein expression levels represent late-stage Alzheimer’s 
disease when the activity of CREB has been shown to be greatly reduced via 
dephosphorylation (223) whereas the one suggesting an increase demonstrate the direct 
effects of Abeta addition to cultured neurons.  The latter study might better reflect our 
results since our experiments were performed at an early stage of AD.   
Alternatively, it has been shown that the maintenance of normal BDNF mRNA 
levels is mainly mediated by NMDA receptors whereas excessive levels of BDNF are 
mediated by non-NMDA receptors (293,294).  Since it has been demonstrated that 
NMDAR activity is reduced in AD, it is possible that the activity of non-NMDA receptors 
is increased to make up for diminished NMDAR activity.  Regulation via non-NMDAR 
pathways could increase BDNF transcription via alternate mechanisms that do not depend 
on CREB for gene activation and thereby, explain our results that suggest an increase in 
BDNF mRNA expression in AD.  Correspondingly, studies indicate that BDNF increases 
the mRNA and protein levels of NMDA receptor subunits as well as their delivery to the 
plasma membrane in cultured hippocampal neurons in order to up-regulate receptor activity 
(46).  Therefore, an attempt to increase BDNF transcription through non-NMDAR could 
represent a compensatory mechanism to help restore NMDAR activity in the early stages of 
AD. 
The aforementioned molecules predominantly participate in LTP.  The increased 
mRNA expression of CREB and BDNF could represent a failed compensatory mechanism 
in the early stages of AD to maintain LTP.  As the disease progresses, it is possible that 
their expression levels become severely diminished as demonstrated by other studies in 
which experiments were conducted in brain samples with late stage AD.  The altered 
expression levels of these molecules might contribute to the diminished prevalence of LTP 
seen in AD.   
For plasticity-related mRNAs principally involved in both LTP and LTD, 
significant changes in the expression level of specific mRNAs (MAP1B, Stau2, αCaMKII, 
BDNF, CREB1, and AGO2) under investigation were observed especially in the 
61 
 
 
hippocampus (CA1-CA3 fields) of 3xTg mice compared to WT mice.  These alterations 
might contribute to the imbalance between LTP and LTD in AD.  On the other hand, some 
of the mRNAs studied showed no significant change in their expression level (Pkcz, CPEB, 
NMDAR1, MAP2, FMRP, and Stau1) between groups.  This demonstrates that the 
expression changes we observed were specific to a subset of plasticity-related mRNAs and 
to specific brain regions.  If all genes had been impaired and in an equal manner for all 
brain regions, it could have been attributed to a general loss of neurons.  Moreover, the 
greater number of genes affected in the hippocampus than in the cortex of 3xTg mice is 
consistent with the progression of AD whereby, in the early stages of the disease, the 
hippocampus (especially the CA1 and CA3 sub-regions) is most vulnerable (244).     
However, the significant changes in mRNA expression for some of the genes 
studied (ex: CREB1, AGO2) were observed for only one reference gene.  Also, for some of 
the other plasticity-related genes investigated, they exhibited a tendency for altered 
expression levels (ex: Arc), but a significant difference could not be established.  This does 
not rule out their potential roles in the progression of AD.  It is possible that a greater 
sample size is required to observe a significant difference in the expression level of these 
mRNAs as well as to reduce the variation between individuals of the same group.   
In addition, more accurate results could be obtained by performing experiments in an 
activated system rather than in unperturbed in vitro preparations.  Yet, there is a possibility 
that defects occur in protein expression rather than mRNA expression or in the localization 
and/or function of mRNAs and proteins.  Nonetheless, it is unmistakable that alterations in 
the expression of specific plasticity-related mRNAs occur at the onset of AD, as observed 
in our study, and likely contribute to the progression of the disease.   
Various possibilities can account for the altered expression levels of the mRNAs 
discussed in AD.  For one, regulation of mRNAs by miRNAs represents a promising 
avenue for further investigations.  miRNAs contribute in governing mRNA turnover and 
translation rates which are of particular importance for altering the levels of expressed 
proteins (295).  Up to now, several miRNAs have been shown to have altered expression 
levels in AD and most likely accelerate the progression of the disease.  Many of these 
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miRNAs such as miR-106 and miR-101 may have a direct role in modulating APP 
expression therefore, potentially participating in excessive amyloid production 
(224,296,297).  Other miRNAs involved in regulating the expression levels of the 
aforementioned plasticity-related mRNAs in AD pathology have yet to be discovered.  
miRNAs could represent an important mechanism by which mRNA and consequently, 
protein expression become altered in AD.  This can contribute to the disrupted synaptic 
function observed in AD. 
 
4.2 Aging 
 
For aging, the results of the qRT-PCR study show that no significant differences were 
observed for the expression profile of plasticity-related mRNAs in the hippocampus of 
young rats compared to aged rats.  However, various other studies have observed age 
related changes in the transcription of plasticity-related mRNAs.  For example, although 
Arc mRNA expression in the cortex and hippocampus of young and aged rats was similar 
for both groups in our experiment, Blalock, E. et al. (298) observed a decreased resting Arc 
expression in the CA1 region of aged rats using microarray analysis.  Additionally, 
Lanahan et al. (299) observed changed expression of another IEG during aging.  They 
found that c-fos mRNA expression increases to a greater extent in aged rats compared to 
young rats upon LTP induction in the hippocampus.  Therefore, the possibility that the 
expression profile of the plasticity-related mRNAs studied changes during aging cannot be 
ruled out.   
Various factors can account for our findings.  For one, the cognitive status of the aged 
rats used in our experiments was not determined.  Although aged Fisher 344 rats are a well-
known model for examining decreased cognitive decline, there is a possibility that the rats 
studied had an intact cognitive status. This could explain the lack of differences observed 
for the expression of the plasticity-related mRNAs under investigation.  Assessing the 
cognitive status of the rats using a memory test such as the Morris water maze prior to 
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experiments could allow the categorization of rats into memory impaired and memory 
unimpaired groups for better results.  Moreover, the sample size was small making it 
difficult to draw conclusive data not to mention the large variations in expression between 
rodents of the same group.  Another caveat is that experiments were performed in 
unperturbed in vitro preparations thereby, revealing resting rates of transcription that may 
not reflect the actual rates occurring when the system is activated.  On the other hand, there 
is a possibility that the transcription of the mRNAs studied remains intact throughout aging 
and rather, defects occur in the localization of the transcripts and/or in the function and/or 
localization of the corresponding protein. 
    
  
5 Conclusion 
A greater number of plasticity-related mRNAs exhibit altered expressions in the 
hippocampus (CA1-CA3 fields) than in the cortex or dentate gyrus of 3xTg mice.  This is 
consistent with the pathology of AD whereby the CA1-CA3 regions of the hippocampus 
are particularly susceptible at the onset of AD (244).  In this region of the brain especially, 
significant increases occur in the expression levels of MAP1B and Stau2 mRNAs in 3xTg 
mice compared to WT mice (Table III and table V).  Upon LTD induction, MAP1B mRNA 
is transported to active synapses under the regulation of Stau2 (88). Once released from the 
translational repression of Stau2, MAP1B locally participates in the internalization of 
synaptic AMPAR to weaken a subsequent synaptic transmission (109).  An increase in the 
expression of these mRNAs possibly stimulates enhanced translation.  Subsequently, the 
resulting proteins likely participate in excessive internalization of AMPAR and thereby, 
contribute to the prevalence of LTD over LTP that occurs in AD (216,217). A significant 
increase in the expression of BDNF, and CREB mRNAs also takes place in the 
hippocampus (CA1-CA3 fields) of 3xTg mice compared to their WT counterpart (Table 
III).  BDNF and CREB proteins mainly participate in LTP by increasing the synthesis of 
NMDAR and the conductance of these receptors (46) and by activating the transcription of 
plasticity-related genes (58), respectively.  An increase in the expression of these mRNAs 
might represent a compensatory mechanism at the onset of AD to restore the balance 
between LTP and LTD by attempting to enhance LTP.  A significant increase was similarly 
observed for AGO2 mRNA in the hippocampus (CA1-CA3 fields) of 3xTg mice compared 
to WT mice (Table V).  AGO2 participates in the regulation of miRNAs.  An increase in its 
mRNA level might promote enhanced translation of AGO2 and thereby, cause an 
imbalance in miRNA expression.  Consequently, the translational regulation of various 
plasticity-related mRNAs may become disrupted.  Finally, the other plasticity-related 
mRNAs investigated appear to remain relatively stable between 3xTg and WT mice at the 
onset of AD in most regions of the brain. 
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Since very few studies have focussed on studying the expression of genes in the early 
stages of AD, our experiments have shed light on which plasticity-related mRNAs first 
exhibit altered expression levels in AD.   
As for the expression levels of plasticity-related mRNAs in aged rats compared to 
young rats, they seem to remain stable between both groups.  However, further studies must 
be conducted in rodents with a pre-established cognitive status (young, aged cognitively 
impaired, and aged cognitively unimpaired) in order to obtain more conclusive results.   
 
5.1 Perspectives 
Various studies have compared the expression of plasticity-related genes between AD 
and control subjects.  However, most of these studies have focussed on moderate to 
advanced stages of AD when molecular pathways are severely dysregulated and 
neurodegeneration is prominent in all regions of the brain (270,273,274).  This makes it 
difficult to develop a progressive model for AD and thereby, to develop pharmaceutical 
interventions aimed at preventing and/or halting the progression of the disease.  It would 
therefore be important to study the expression of various plasticity-related genes at several 
stages of the disease, especially at the onset of AD, in different brain tissues such as the 
cortex and sub-regions of the hippocampus to determine which molecular pathways are 
initially disrupted.  This can be achieved using microarrays or qRT-PCR experiments. 
Western blots should be performed in parallel in AD and control subjects to 
determine if there is a discrepancy between protein expressions between groups.  This 
could help determine if dysregulations in AD occur at the transcriptional and/or at the 
translational level.  In the case that disruptions are observed at the translational level, the 
study of miRNAs is a great approach since miRNAs are known to regulate the translation 
of mRNAs.  Not to mention that several miRNAs display altered expression levels in AD 
(226-228). 
On the other hand, if no changes in gene and protein expressions are observed, FISH 
and immunohistochemistry experiments should be conducted to determine if defects occur 
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in the localization of the mRNAs and proteins, respectively.  In parallel, the function of the 
proteins should also be verified by means of proteomics. 
The aforementioned studies should also be performed in cognitively impaired, 
cognitively unimpaired, and young rodents for a large sample size to determine which 
molecular pathways become disrupted during age-related cognitive decline in the absence 
of neurodegeneration 
Ultimately, better understanding the sequential process through which molecular 
pathways become dysregulated during age-related cognitive decline and AD and how they 
become dysregulated, would help provide the necessary tools to create a comprehensive 
model on the progression of these conditions.  This would enable health professionals to 
develop effective pharmaceutical interventions for the prevention and/or treatment of age-
related cognitive decline and AD. 
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